

SECRETED PEPTIDES

FIELD OF THE INVENTION

The invention relates to secreted active peptides, isolated polynucleotides encoding such peptides, polymorphic variants thereof, and the use of said nucleic acids and peptides or compositions thereof in detection assays, for disease diagnosis, for disease treatment and for drug development.

BACKGROUND

Defensin and cathelicidin are the two major families of mammalian cationic anti-microbial proteins (Yang D, Chertov O, Oppenheim JJ, Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37), *Journal Leukocyte Biology*, (2001), May;69(5):691-7). These proteins contribute to the natural immunity by disrupting the bacterial cell membrane and by binding to and neutralizing the effects of endotoxin (Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R, Cathelicidin peptides as candidates for a novel class of antimicrobials, *Current Pharmaceutical Design*, (2002) 8:779-93). They are also known for their chemotaxis on host cells, such as mast cells.

Cathelicidins are stored as precursors in cytoplasmic granules of neutrophil leukocyte (Zanetti M, Gennaro R, Romeo D, Cathelicidins: a novel protein family with a common proregion and variable C-terminal antimicrobial domain, *FEBS Lett.*, (1995), 374(1):1-5). Members of the cathelicidin family contain a conserved pro-part of the cathelin type at their N-terminal end.

There is so far only one cathelicidin family member known in humans, termed FALL-39 (Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R, The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes, *European Journal of Biochemistry*, (1996), Jun 1;238(2):325-32). This gene has four exons, its product is hCAP-18. Exon 4 contains the sequence of the mature C-terminal antibacterial peptide: LL37.

LL37 is liberated by proteinase 3 (Sorensen OE, et al., Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3, *Blood*, (2001), Jun 15;97(12):3951-9; Lehrer RI, Ganz T, Cathelicidins : a family of endogenous antimicrobial peptides, *Current opinion in hematolgy*, (2002), Jan;9(1):18-22). This peptide induces chemotactic activity and degranulation in mast cells through a Gi protein-phospholipase C signaling pathway and by mobilizing intracellular Ca ++ (Niyonsaba F, et al., A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis, *Immunology*, (2002), May;106(1):20-6).

Resistance to classical antibiotics is an increasing clinical problem. The present invention

of human antibacterial peptide LL-37 induces mast cell chemotaxis, *Immunology*, (2002), May;106(1):20-6).

Resistance to classical antibiotics is an increasing clinical problem. The present invention provides new, biologically active, antimicrobial polypeptides which are different from classical antibiotics, such as penicillins and tetracyclines. Antimicrobial peptides of animal origin are of particular importance, as they generally exhibit activity against antibiotic-resistant bacterial strains (Steinberg et al., 1996, "Protegrins: Fast Acting Bactericidal Peptides," presented at: Intl. Symposium on Staphylococci and Staphylococcus Infections, Aix les Bains, France and US Patent 5,994,306). Peptides composed of L-amino acids, however, undergo rapid proteolysis in the gut, making oral administration difficult. Additionally, peptides degrade fairly rapidly in serum and therefore must be administered in large doses, increasing both the risk of side effects and the cost of treatment. Cyclic peptides are more resistant to proteolytic degradation and therefore have a greater potential for oral administration and/or lower dosage levels than non-cyclized peptides. Cyclization also confers structural stability without interfering with the side chains necessary for bioactivity, potentially leading to greater efficacy. The peptides of the invention also show sequence and structural homology with a number of antiviral active peptides reported to have a cyclic structure (Frechet D, et al., *Biochemistry*, 1994 Jan 11;33(1):42-50; Constantine KL, et al., *J Biomol NMR* 1995 Apr;5(3):271-86; Katahira R, et al., *Bioorg Med Chem.* 1996 Jan;4(1):121-9).

Thus, the present invention provides advantageous and novel compositions for reducing viral and microbial infection and treating disorders resulting from viral and microbial activity.

SUMMARY OF THE INVENTION

The present invention is directed to compositions related to secreted active peptides, designated herein "Pep714-related" peptides. Such compositions include the Pep714 peptide, having an amino acid sequence of SEQ ID 6, Pep714-related peptides, Pep714-related peptide precursors, Pep714-related antibodies, including monoclonal antibodies and other binding compositions derived therefrom, and methods of making and using these compositions. Pep714-related peptide precursors of the invention include the Pep714 peptide precursors of SEQ ID NO: 1 to 5.

A preferred embodiment of the invention includes Pep714-related peptides having a posttranslational modification, such as a phosphorylation, glycosylation, acetylation, amidation, or an N- or O- linked carbohydrate group. Additionally preferred are Pep714-related peptides with intra- or inter-molecular interactions, e.g., disulfide and hydrogen bonds, that result in higher order structures. Also preferred are Pep714-related peptides that result from differential mRNA processing or splicing.

In another aspect, the invention includes polynucleotides coding for a polypeptide having an amino acid sequence of SEQ ID NO: 6, antisense oligonucleotides complementary to such sequences, oligonucleotides complementary to Pep714 gene sequences useful in diagnostic and analytical assays, such as primers for polymerase chain reactions (PCRs), and vectors for expressing

5 Pep714 peptides. In another aspect, the invention includes Pep714-related polypeptides having a sequence which is at least 95 percent identical to SEQ ID NO:6. Preferably, the invention includes polypeptides having at least 97 percent, and more preferably at least 98 percent, and still more preferably at least 99 percent, identity with the sequence from SEQ ID NO:6.

The invention further includes methods of using Pep714-related compositions, including antisense and antibody compounds, to treat disorders associated with aberrant expression or processing of the Pep714-related peptides of SEQ ID NOs:3-6 in an individual, and methods of using Pep714-related compositions, including primers complementary to the Pep714 gene and/or messenger RNA and anti-Pep714-related antibodies, for detecting and measuring quantities of the Pep714-related peptides in tissues and biological fluids. The invention also further includes methods of screening for compounds that inhibit or increase the expression of Pep714-related peptides, as well as methods of screening for compounds that interact with and/or inhibit or increase the activity of Pep714-related peptides. The invention further encompasses compounds thus identified, as well as compositions thereof.

In an additional aspect, the invention includes modified Pep714-related peptides. Such modifications include protecting/blocking groups, linkage to an antibody molecule or other cellular ligand, and detectable labels, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein. Chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formylation, oxidation, reduction, or 25 metabolic synthesis in the presence of tunicamycin. Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased 30 immunogenicity (e.g., water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol). Pep714-related peptides are modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

A preferred aspect of the invention provides a composition comprising an isolated Pep714-related peptide, i.e., a Pep714-related peptide free from proteins or protein isoforms having a significantly different isoelectric point or a significantly different apparent molecular weight from 35 the Pep714-related peptide. The isoelectric point and molecular weight of a Pep714-related peptide

may be indicated by affinity and size-based separation chromatography, 2-dimentional gel analysis, and mass spectrometry.

In a preferred aspect, the invention provides particular polypeptide species that comprise an amino acid sequence selected from the group consisting of SEQ ID NOs:3-6. Preferably, the particular polypeptide species further comprises contiguous amino acid sequence from SEQ ID NO:1. Preferred species are polypeptides that i) comprise an amino acid sequence selected from the group consisting of SEQ ID NOs:3-6; ii) appear in human blood serum; and iii) result from proteolytic processing of the polypeptide of SEQ ID NO:1.

In another aspect, the invention includes isolated antibodies specific for any of the polypeptides, peptide fragments, or peptides described above. Preferably, the antibodies of the invention are monoclonal antibodies. Further preferred are antibodies that bind to a Pep714-related peptide exclusively, that is, antibodies that do not recognize other polypeptides with high affinity. Anti-Pep714-related peptide antibodies have purification, diagnostic and therapeutic applications, particularly in treating Pep714-related peptide-related disorders. Preferred anti- Pep714-related peptide antibodies for purification and diagnosis are attached to a label group.

Also included in the invention are methods to inhibit the growth of or kill microorganisms. For example, Pep714 peptide or Pep714-related peptides may be used as disinfectants, preservatives, or in methods of reducing microbial infections, and methods of treating microbial infection or disorders resulting from such infection. Such methods rely on Pep714 peptide, Pep714-related peptide, and Pep714-related peptide precursor compositions.

The present invention also includes compositions and methods to treat a virally infected individual, animal or human. Preferably, such compositions and methods are used for inhibiting the growth or replication of a virus. It is also preferred that the compositions and methods are used for therapeutic or prophylactic treatment of individuals infected with a virus or who are at risk for viral infection, respectively, or to treat objects or materials, such as medical equipment and supplies, or biological fluids, such as blood, blood products, and tissues, to prevent viral infection of an individual.

In another aspect, the invention includes isolated antibodies specific for any of the polypeptides, peptide fragments, or peptides described above. Preferably, the antibodies of the invention are monoclonal antibodies. Such antibodies have diagnostic and therapeutic applications, particularly in treating Pep714-related disorders. Treatment methods include, but are not limited to, those that employ antibodies or antibody-derived compositions specific for a Pep714-related antigen. Diagnostic methods for detecting Pep714-related peptides in specific tissue samples, and for detecting levels of expression of Pep714-related peptides in tissues, also form part of the invention. Compositions comprising one or more antibodies described above, together with a pharmaceutically

acceptable carrier are also within the scope of the invention.

In another aspect, the invention includes an isolated polynucleotide that encodes a Pep714 peptide having the amino acid sequence of SEQ ID NO:6.

In another aspect, the invention includes primer pairs for carrying out a PCR to amplify a segment of a polynucleotide of the invention. Each primer of a pair is an oligonucleotide having a length of between 15 and 30 nucleotides such that i) one primer of the pair forms a perfectly matched duplex with one strand of a polynucleotide of the invention and the other primer of the pair forms a perfectly matched duplex with the complementary strand of the same polynucleotide, and ii) the primers of a pair form such perfectly matched duplexes at sites on the polynucleotide that are separated by a distance of between 10 and 2500 nucleotides. Preferably, the annealing temperature of each primer of a pair with its respective complementary sequence is substantially the same.

In another aspect, the invention includes natural variants of the Pep714 peptide having a frequency in a selected population of at least two percent. More preferably, such natural variant has a frequency in a selected population of at least five percent, and still more preferably, at least ten percent. Most preferably, such natural variant has a frequency in a selected population of at least twenty percent. The selected population may be any recognized population of study in the field of population genetics. Preferably, the selected population is Caucasian, Negroid, or Asian. More preferably, the selected population is French, German, English, Spanish, Swiss, Japanese, Chinese, Irish, Korean, Singaporean, Icelandic, North American, Israeli, Arab, Turkish, Greek, Italian, Polish, Pacific Islander, Finnish, Norwegian, Swedish, Estonian, Austrian, or Indian. More preferably, the selected population is Icelandic, Saami, Finnish, French of Caucasian ancestry, Swiss, Singaporean of Chinese ancestry, Korean, Japanese, Quebecian, North American Pima Indians, Pennsylvanian Amish and Amish Mennonite, Newfoundland, or Polynesian.

In another aspect, the invention provides a vector comprising DNA encoding a Pep714-related peptide. The invention also includes host cells and transgenic non human animals comprising such a vector. There is also provided a method of making a Pep714-related peptide or Pep714-related peptide precursor. One preferred method comprises the steps of (a) providing a host cell containing an expression vector as disclosed above; (b) culturing the host cell under conditions whereby the DNA segment is expressed; and (c) recovering the protein encoded by the DNA segment. Another preferred method comprises the steps of: (a) providing a host cell capable of expressing a Pep714-related peptide; (b) culturing said host cell under conditions that allow expression of said Pep714-related peptide; and (c) recovering said Pep714-related peptide. Within one embodiment the expression vector further comprises a secretory signal sequence operably linked to the DNA segment, the cell secretes the protein into a culture medium, and the protein is recovered from the medium. An especially preferred method of making a Pep714-related peptide includes chemical

synthesis using standard peptide synthesis techniques, as described in the section titled "Chemical Manufacture of Pep714-related compositions" and in Example 3.

In still a further aspect, the invention includes pharmaceutical compositions and formulations comprising a polypeptide having an amino acid sequence of SEQ ID 6, and a pharmaceutically acceptable carrier compound.

5 Further aspects of the invention are also described in the specification and in the claims.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

10

SEQ ID	content
1	Fall-39 preprotein
2	Fall-39 protein
3	peptide 1
4	peptide 2
5	peptide 3
6	peptide 4 (Pep714)

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the C-term sequence of the Fall-39 protein. The tryptic peptides observed by tandem mass spectrometry are bold and underlined. The ones observed by tandem and MALDI mass spectrometry are bold, underlined and in italics. The signal peptide of the Fall-39 protein has been underlined.

15 Figure 2 illustrates the sequence alignment of the Pep714 peptide of the invention (SEQ ID 6) and a structurally related peptide, RBP.

20 Figure 3 is a ribbon diagram depicting the predicted structure of the Fall-39 propeptide, as defined in the Swiss-Prot entry P49913. This is the full-length protein after removal of the signal peptide (30 amino acids at the N-terminus) and after cleavage of the anti-bacterial protein FALL-39 (39 amino acids at the C-terminus). Amino acids are numbered according to their position in the full-length Fall-39 preprotein (SEQ ID NO:1). The disulfide bonds C86-C97 and C108-C125 are attributed by similarity and by *ab initio* folding. The Pep714 peptide of the invention, defined as residues C108 to R131, and when it is still attached to the propeptide, can be seen to form a double stranded beta sheet structure on the forefront of the Figure.

25 Figure 4 is a ribbon diagram of a predicted structure for Pep714. In particular, the closure of

the ring is predicted to be achieved through an amide bond between the side-chain of D128 (D21 in SEQ ID NO:6) and C108 (C1 in SEQ ID NO:6).

DETAILED DESCRIPTION OF THE INVENTION

5

The present invention described in detail below provides methods, compositions, and kits useful for screening, diagnosis, and treatment of a microbial or viral infection of a mammalian individual; for identifying individuals most likely to respond to a particular therapeutic treatment; for monitoring the results of antimicrobial or antiviral therapy; for screening Pep714-related peptide modulators; and for drug development. When the invention is used for drug development, e.g., to determine the ability of a Pep714-related modulator or drug candidate to induce an antimicrobial or antiviral response, the body fluid analyzed for the level of at least one Pep714-related peptide is preferably from a non-human mammal. The nonhuman mammal is preferably one in which the induction of an antiviral or antimicrobial response by endogenous and/or exogenous agents is predictive of the induction of such a response in a human. Rodents (mice, rats, etc,) and primates are particularly suitable for use in this aspect of the invention. The invention also encompasses the administration of therapeutic compositions to a mammalian individual to treat or prevent microbial or viral infection and related disorders. The mammalian individual may be a non-human mammal, but is preferably human, more preferably a human adult. For clarity of disclosure, and not by way of limitation, the invention will be described with respect to the analysis of blood plasma samples. However, as one skilled in the art will appreciate, the assays and techniques described below can be applied to other biological fluid samples (e.g. cerebrospinal fluid, lymph, bile, plasma, saliva or urine) or tissue samples from an individual at risk of having or developing a microbial or viral infection or related disorder. The methods and compositions of the present invention are useful for screening, diagnosis and prognosis of a living individual, but may also be used for postmortem diagnosis in an individual, for example, to identify family members who are at risk of developing the same disorder.

Definitions

30 As used herein, the term "nucleic acids" and "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. Throughout the present specification, the expression "nucleotide sequence" may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression "nucleotide sequence" encompasses the nucleic

material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule. Also, used interchangeably herein are terms "nucleic acids", "oligonucleotides", and "polynucleotides".

5 An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated Pep714-related nucleic acid molecule 10 can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant 15 techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. A nucleic acid molecule of the present invention can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid, as a hybridization probe, Pep714-related nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning. A Laboratory Manual.* 2nd, ed., Cold Spring Harbor 20 Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to Pep714-related nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an 25 automated DNA synthesizer.

As used herein, the term "hybridizes to" is intended to describe conditions for moderate stringency or high stringency hybridization, preferably where the hybridization and washing conditions permit nucleotide sequences at least 60% homologous to each other to remain hybridized 30 to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85%, 90%, 95% or 98% homologous to each other typically remain hybridized to each other. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are as 35 follows: the hybridization step is realized at 65°C in the presence of 6 x SSC buffer, 5 x Denhardt's

solution, 0,5% SDS and 100µg/ml of salmon sperm DNA. The hybridization step is followed by four washing steps:

- two washings during 5 min, preferably at 65°C in a 2 x SSC and 0.1%SDS buffer;
- one washing during 30 min, preferably at 65°C in a 2 x SSC and 0.1% SDS buffer,
- one washing during 10 min, preferably at 65°C in a 0.1 x SSC and 0.1%SDS buffer,

5 these hybridization conditions being suitable for a nucleic acid molecule of about 20 nucleotides in length. It will be appreciated that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art, for example be adapted according to the teachings disclosed in Hames B.D. and

10 Higgins S.J. (1985) Nucleic Acid Hybridization: A Practical Approach. Hames and Higgins Ed., IRL Press, Oxford; and Current Protocols in Molecular Biology (supra).

“Percent homology” is used herein to refer to both nucleic acid sequences and amino acid sequences. To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the 15 sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90% or 95% of the length of 20 the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent 25 homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology= # of identical positions/total # of positions 100).

The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example 30 of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77, the disclosures of which are incorporated herein by reference in their entireties. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide 35 searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain

nucleotide sequences homologous to the sequences of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the polypeptide sequences of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Research 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>, the disclosures of which are incorporated herein by reference in their entireties. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989), the disclosures of which are incorporated herein by reference in their entireties. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-translational modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl, acetyl, phosphate, amide, lipid, carboxyl, acyl or carbohydrate groups are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term "protein" as used herein may be used synonymously with the term "polypeptide" or may refer to, in addition, a complex of two or more polypeptides which may be linked by bonds other than peptide bonds, for example, such polypeptides making up the protein may be linked by disulfide bonds. The term "protein" may also comprehend a family of polypeptides having identical amino acid sequences but different post-translational modifications, particularly as may be added when such proteins are expressed in eukaryotic hosts.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the Pep714-related peptide, or a biologically active fragment or homologue thereof is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a protein according to the invention (e.g. Pep714-related peptide, or a biologically active fragment or homologue thereof) in

which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of a protein according to the invention having less than about 30% (by dry weight) of protein other than the Pep714-related peptide (also referred to herein as a "contaminating protein"), more preferably less than about 20% of protein other than the protein according to the invention, still more preferably less than about 10% of protein other than the protein according to the invention, and most preferably less than about 5% of protein other than the protein according to the invention. When the protein according to the invention or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of Pep714-related peptide, or a biologically active fragment or homologue thereof in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of a Pep714-related peptide having less than about 30% (by dry weight) of chemical precursors or non-Pep714-related peptides chemicals, more preferably less than about 20% chemical precursors or non-Pep714-related peptides chemicals, still more preferably less than about 10% chemical precursors or non-Pep714-related peptides chemicals, and most preferably less than about 5% chemical precursors or non-Pep714-related peptides chemicals.

The term "recombinant polypeptide" is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

The term "Pep714 peptide" refers to a peptide comprising the sequence described by SEQ ID NO:6. Such peptide may be post-translationally modified, for example, phosphorylated, acylated, or glycosylated. Pep714 peptide may also contain other structural or chemical modifications such as disulfide linkages or amino acid side chain interactions such as hydrogen and amide bonds that result in complex secondary and tertiary structures.

The terms "Pep714-related peptide" and "Pep714-related peptides" are used herein to embrace any and all of the peptides, polypeptides and proteins of the present invention. These include mutant polypeptides, such as deletion, addition, swap, or truncation mutants, fusion polypeptides comprising such polypeptides, and polypeptide fragments of at least three, but preferably 8, 10, 12, 15, or 21 contiguous amino acids of the sequence of SEQ ID NO:6. The

invention embodies polypeptides encoded by the nucleic acid sequences of the Pep714 gene or messenger RNA, as well as the Pep714-related peptides from humans, including isolated or purified Pep714-related peptides consisting of, consisting essentially of, or comprising the sequence of SEQ ID NO: 6. Preferred Pep714-related peptides retain at least one biological activity of Pep714.

5 The term "biological activity" as used herein refers to any function carried out by Pep714. These include but are not limited to: (1) forming intermolecular amino acid side chain interactions such as hydrogen, amide, or disulfide links; (2) forming secondary and/or tertiary structures, preferably cyclic structures; antigenicity, or the ability to bind an anti-Pep714-related peptide specific antibody; (4) immunogenicity, or the ability to generate an anti-Pep714-related peptide specific antibody; (5) antimicrobial activity; (6) antiviral activity (e.g., prevention of virus- host cell interactions); (7) mediating levels of a Pep714-related peptide substrate protein; (8) mediating cell proliferation or cell cycle; or (9) interacting with a Pep714-related target molecule, preferably a protein, e.g. a substrate protein or protein similar to a substrate, such as a viral envelope protein, preferably an HIV envelope protein.

10 15 Another aspect of the invention pertains to anti-Pep714-related antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as a Pep714-related peptide, or a biologically active fragment or homologue thereof. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind a Pep714-related peptide, or a biologically active fragment or homologue thereof. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of 20 25 immunoreacting with a particular epitope of a Pep714-related peptide. A monoclonal antibody composition thus typically displays a single binding affinity for a particular Pep714-related peptide with which it immunoreacts.

30 As used herein, a "label group" is any compound that, when attached to a polynucleotide or polypeptide (including antibodies), allows for detection or purification of said polynucleotide or polypeptide. Label groups may be detected or purified directly or indirectly by a secondary compound, including an antibody specific for said label group. Useful label groups include 35 radioisotopes (e.g., ³²P, ³⁵S, ³H, ¹²⁵I), fluorescent compounds (e.g., 5-bromodesoxyuridin, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, phycoerythrin acetylaminofluorene, digoxigenin), luminescent compounds (e.g., luminol, GFP, luciferin, aequorin), enzymes or enzyme co-factor detectable labels

(e.g., peroxidase, luciferase, alkaline phosphatase, galactosidase, or acetylcholinesterase), or compounds that are recognized by a secondary factor such as strepavidin, GST, or biotin. Preferably, a label group is attached to a polynucleotide or polypeptide in such a way as to not interfere with the biological activity of the polynucleotide or polypeptide.

5 Radioisotopes may be detected by direct counting of radioemission, film exposure, or by scintillation counting, for example. Enzymatic labels may be detected by determination of conversion of an appropriate substrate to product, usually causing a fluorescent reaction. Fluorescent and luminescent compounds and reactions may be detected by, e.g., radioemission, fluorescent microscopy, fluorescent activated cell sorting, or a luminometer.

10 As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are 15 introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, 20 expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

25 As used herein, "effective amount" describes the amount of an agent, preferably a Pep714-related peptide of the invention, sufficient to have a desired effect. For example, an antimicrobially effective amount is the amount of an agent required to reduce the concentration of a targeted microbe in a given sample by at least 1, 2, 5, 10, 15, or preferably 25%. An antimicrobially effective amount also describes the amount of an agent required to ameliorate a symptom of a microbially-caused disorder in an individual, such as a bacterial, yeast, or fungal infection. An antivirally effective amount refers to the amount of an agent required to reduce viral infectivity by at least 1, 2, 5, 10, 15, or preferably 25%. An antivirally effective amount also describes the amount required to reduce viral titer in an individual by at least 1, 2, 5, 10, 15, or preferably 25%. The term may also describe the amount of an agent required to ameliorate a symptom of a virally-caused disorder in an 30 individual. The effective amount for a particular patient may vary depending on such factors as the diagnostic method of the symptom being measured, the state of the condition being treated, the 35

overall health of the patient, method of administration, and the severity of side-effects.

Pep714-related peptides of the invention

The Pep714 peptide of the invention is listed in SEQ ID NO: 6. This peptide was found to be 5 secreted and predicted to be a cyclic, active peptide which is released from its precursors by dibasic cleavage. The human cathelicidin is known to be processed by proteinase 3 to yield to the antimicrobial peptide LL-37 (Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N, Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3, *Blood*, (2001), Jun 15;97(12):3951-9 and US Patent number 10 6,103,888). The Pep714-related peptides of the invention, however, are located on the remaining N-terminal part of the precursor, just before the reported NKRFA-LLGDF cleavage site (Sorensen et al., *supra*).

The Pep714-related peptides of the invention show sequence and structural homology with a 15 number of antiviral active peptides reported to have a cyclic structure (Frechet D, et al., Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus, *Biochemistry*, 1994 Jan 11;33(1):42-50; Constantine KL, et al, High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion, *J Biomol NMR* 1995 Apr;5(3):271-86; Katahira R, et al., MS-271, a novel inhibitor of calmodulin-activated 20 myosin light chain kinase from Streptomyces sp.--II. Solution structure of MS-271: characteristic features of the "lasso" structure, *Bioorg Med Chem*. 1996 Jan;4(1):121-9). Figure 2 illustrates the sequence alignment of Pep714 peptide with 1RPB (also RP 71955 or siamycin). Figure 3 depicts a predicted fold for the Fall-39 propeptide, *i.e.* the chain remaining after removal of the signal 25 sequence (30 amino acids at the N-terminus) and after cleavage of the anti-bacterial protein FALL-39 (39 amino acids at the C-terminus). The Pep714 peptide of the invention (residues C108 to R131), while attached to the propeptide, can be seen to form a double-stranded beta sheet structure, closed at one end by a loop, and at the other end by the disulfide bond C108-C125. Figure 4 30 illustrates a predicted structure of Pep714, based on stabilization of the cyclic structure by an amide bond between the aspartate residue at position 21 (in SEQ ID NO:6) and the cysteine residue at position 1 (in SEQ ID NO:6). As is obvious from visual comparison of the folding patterns of the propeptide (Figure 3) and the processed Pep714 peptide (Figure 4), the Pep714 peptide possesses different structural properties once it has been released from the propeptide and thus presents unique sites for interaction (e.g., protein-protein interactions) which were sterically hindered before the structural rearrangements.

The Pep714-related peptides of the invention therefore represent new active peptides, which 35 are produced by dibasic cleavage of a known precursor of antibacterial peptides. Moreover, these

new peptides show structural homology with otherwise unrelated peptides whose structure is known to be cyclic. Cyclisation of peptides has also been proposed elsewhere as a basis to yield active peptides having broad spectrum antimicrobial activity (US Patent 5,916,872). Thus, the Pep714-related peptides of the invention can be used in a wide variety of applications to inhibit the growth of or kill microorganisms. For example, the Pep714-related peptides can be used as disinfectants or as preservatives for materials such as foodstuffs, cosmetics, medicaments and other nutrient-containing materials. The Pep714-related peptides can also be used to treat or prevent diseases related to microbial infection in both plants and animals.

Pep714-related peptides are very similar to the siamycin family of antiviral peptides in both sequence and higher order structure. Pep714-related peptides can be used to treat a virally infected individual, animal or human. Such peptides are particularly useful for inhibiting the growth or replication of a virus, preferably HIV-1 and HIV-2. The Pep714-related peptides are also useful in the therapeutic or prophylactic treatment of individuals infected with a virus or who are at risk for viral infection, respectively. Such peptide compositions also can be used to treat objects or materials, such as medical equipment, supplies, or fluids, including biological fluids, such as blood, blood products, and tissues, to prevent viral infection of an individual.

The terms "Pep714-related peptide" and "Pep714-related peptides" are used herein to embrace any and all of the peptides, polypeptides and proteins of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies polypeptides encoded by the nucleic acid sequences of the Pep714 gene, as well as the Pep714-related peptides from humans, including isolated or purified Pep714-related peptides consisting of, consisting essentially of, or comprising the sequence of SEQ ID NO: 6.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least three, but preferably 8, 10, 12, 15, or 21 contiguous amino acids of the sequence of SEQ ID NO: 6. In preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the Pep714-related peptide sequence. The invention also concerns the polypeptide encoded by the Pep714-related nucleotide sequences of the invention, or a complementary sequence thereof or a fragment thereof.

One aspect of the invention pertains to isolated Pep714-related peptides, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-Pep714-related antibodies. In one embodiment, native Pep714-related peptides can be isolated from plasma, cells or tissue sources by an appropriate purification scheme using standard protein

purification techniques. In another embodiment, Pep714-related peptides are produced by recombinant DNA techniques. Alternative to recombinant expression, a Pep714-related peptide or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

Typically, biologically active portions comprise a domain or motif with at least one activity of 5 a Pep714-related peptide.

A biologically active Pep714-related peptide may, for example, comprise at least 1, 2, 3, or 5 amino acid changes from the sequence of SEQ ID NO: 6, or comprise at least 1%, 2%, 3%, 5%, 8%, 10% or 15% changes in amino acids from the sequence of SEQ ID NO: 6.

In a preferred embodiment, a Pep714-related peptide comprises a Pep714-related-target 10 binding region and/or a signal-anchor sequence. The invention also concerns the polypeptide encoded by the Pep714-related nucleotide sequences of the invention, or a complementary sequence thereof or a fragment thereof.

In other embodiments, the Pep714-related peptide is substantially homologous to the 15 sequences of SEQ ID NO: 6, and retains the functional activity of the Pep714-related peptide, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described further herein. Accordingly, in another embodiment, the Pep714-related peptide is a protein which comprises an amino acid sequence which shares more than about 60% but less than 100% homology 20 with the amino acid sequence of SEQ ID NO: 6 and retains the functional activity of the Pep714-related peptides of SEQ ID NO: 6. Preferably, the protein is at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or 99.8% homologous to SEQ ID NO: 6, but is not identical to SEQ ID NO: 6. Preferably the Pep714-related peptides is less than identical (e.g. 100% identity) to a naturally occurring Pep714-related peptides. Percent homology can be determined as further detailed above.

15 *Pep714-related nucleic acids*

One aspect of the invention pertains to purified or isolated nucleic acid molecules that encode 30 Pep714-related peptides or biologically active portions thereof as further described herein, as well as nucleic acid fragments thereof. Said nucleic acids may be used for example in therapeutic and diagnostic methods and in drug screening assays as further described herein.

An object of the invention is a purified, isolated, or recombinant nucleic acid coding for a 35 Pep714-related peptide, complementary sequences thereto, and fragments thereof. The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide coding for a Pep714-related peptide, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide coding for a Pep714-related peptide, or a sequence complementary

thereto or a biologically active fragment thereof. Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide coding for a Pep714-related peptide, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

In another preferred aspect, the invention pertains to purified or isolated nucleic acid molecules that encode a portion or variant of a Pep714-related peptide, wherein the portion or variant displays a Pep714-related biological activity of the invention. Preferably said portion or variant is a portion or variant of a naturally occurring full-length Pep714-related peptide.

Another object of the invention is a purified, isolated, or recombinant nucleic acid encoding a Pep714-related peptide comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6, or fragments thereof, wherein the isolated nucleic acid molecule encodes one or more motifs selected from the group consisting of a Pep714-related target binding region, a signal-anchor sequence and a substrate specificity determining region. For example, the purified, isolated or recombinant nucleic acid may comprise genomic DNA or fragment thereof which encodes the polypeptide of SEQ ID NO: 6 or a fragment thereof, wherein the isolated nucleic acid molecule encodes one or more motifs selected from the group consisting of a Pep714-related target binding region and a signal providing for secretion. Any combination of said motifs may also be specified.

The nucleotide sequence determined from the cloning of the Pep714 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other Pep714-related peptides family members (e.g. sharing the novel functional domains), as well as Pep714-related peptides homologues from other species.

A nucleic acid fragment encoding a "biologically active portion of a Pep714-related peptide" can be prepared by isolating a portion of a nucleotide sequence coding for a Pep714-related peptide, which encodes a polypeptide having a Pep714-related peptides biological activity, expressing the encoded portion of the Pep714-related peptide (e.g., by recombinant expression in vitro or in vivo) and assessing the activity of the encoded portion of the Pep714-related peptide.

The invention further encompasses nucleic acid molecules that differ from the Pep714-related nucleotide sequences of the invention due to degeneracy of the genetic code and encode the same Pep714-related peptides and fragment of the invention.

In addition to the Pep714-related nucleotide sequences described above, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the Pep714-related peptides may exist within a population (e.g., the human population). Such genetic polymorphism may exist among individuals within a population due to

natural allelic variation. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the Pep714 gene or nucleic acid sequence encoding Pep714-related peptide.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the

Pep714-related nucleic acids of the invention can be isolated based on their homology to the

5 Pep714-related nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

It will be appreciated that the invention comprises polypeptides having an amino acid sequence encoded by any of the polynucleotides of the invention.

10

Uses of Pep714-related nucleic acids

Polynucleotide sequences (or the complements thereof) encoding Pep714-related peptides have various applications, including uses as hybridization probes, in chromosome and gene mapping, and in the generation of antisense RNA and DNA. In addition, Pep714-related peptides-
15 encoding nucleic acids are useful as targets for pharmaceutical intervention, e.g. for the development of DNA vaccines or antisense compositions, and for the preparation of Pep714-related peptides by recombinant techniques, as described herein. The polynucleotides described herein, including sequence variants thereof, can be used in diagnostic assays. Accordingly, diagnostic methods based on detecting the presence of such polynucleotides in body fluids or tissue samples are a feature of
20 the present invention. Examples of nucleic acid based diagnostic assays in accordance with the present invention include, but are not limited to, hybridization assays, e.g., in situ hybridization, and PCR-based assays. Polynucleotides, including extended length polynucleotides, sequence variants and fragments thereof, as described herein, may be used to generate hybridization probes or PCR primers for use in such assays. Such probes and primers will be capable of detecting polynucleotide
25 sequences, including genomic sequences that are similar, or complementary to, the Pep714-related peptides polynucleotides described herein.

The invention includes primer pairs for carrying out a PCR to amplify a segment of a polynucleotide of the invention. Each primer of a pair is an oligonucleotide having a length of between 15 and 30 nucleotides such that i) one primer of the pair forms a perfectly matched duplex
30 with one strand of a polynucleotide of the invention and the other primer of the pair form a perfectly match duplex with the complementary strand of the same polynucleotide, and ii) the primers of a pair form such perfectly matched duplexes at sites on the polynucleotide that separated by a distance of between 10 and 2500 nucleotides. Preferably, the annealing temperature of each primer of a pair to its respective complementary sequence is substantially the same.

35 Hybridization probes derived from polynucleotides of the invention can be used, for

example, in performing *in situ* hybridization on tissue samples, such as fixed or frozen tissue sections prepared on microscopic slides or suspended cells. Briefly, a labeled DNA or RNA probe is allowed to bind its DNA or RNA target sample in the tissue section on a prepared microscopic, under controlled conditions. Generally, dsDNA probes consisting of the DNA of interest cloned into 5 a plasmid or bacteriophage DNA vector are used for this purpose, although ssDNA or ssRNA probes may also be used. Probes are generally oligonucleotides between about 15 and 40 nucleotides in length. Alternatively, the probes can be polynucleotide probes generated by PCR random priming primer extension or *in vitro* transcription of RNA from plasmids (riboprobes). These latter probes are typically several hundred base pairs in length. The probes can be labeled by any of a number of 10 label groups and the particular detection method will correspond to the type of label utilized on the probe (e.g., autoradiography, X-ray detection, fluorescent or visual microscopic analysis, as appropriate). The reaction can be further amplified *in situ* using immunocytochemical techniques directed against the label of the detector molecule used, such as an antibody directed to a fluorescein 15 moiety present on a fluorescently labeled probe. Specific labeling and *in situ* detection methods can be found, for example, in Howard, G. C., Ed., *Methods in Nonradioactive Detection*, Appleton & Lange, Norwalk, Conn., (1993), herein incorporated by reference.

Hybridization probes and PCR primers may also be selected from the genomic sequences corresponding to the full-length proteins identified in accordance with the present invention, including promoter, enhancer elements and introns of the gene encoding the naturally occurring 20 polypeptide. Nucleotide sequences encoding a Pep714-related peptide can also be used to construct hybridization probes for mapping the gene encoding that Pep714-related peptides and for the genetic analysis of individuals. Individuals carrying variations of, or mutations in the gene encoding a 25 Pep714-related peptides of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including, for example, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, et al. *Nature* 324:163-166 (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers 30 complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical 35 cleavage method (e.g. Cotton, et al., *Proc. Natl. Acad. Sci. USA* 85:4397-4401 (1985)), or by differences in melting temperatures. "Molecular beacons" (Kostrikis L. G. et al., *Science* 279:1228-

1229 (1998)), hairpin-shaped, single-stranded synthetic oligonucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used to detect point mutations or other sequence changes as well as monitor expression levels of Pep714-related peptides.

5

Oligonucleotide and Antisense Compounds.

Oligonucleotides of the invention, including PCR primers and antisense compounds, are synthesized by conventional means on a commercially available automated DNA synthesizer, e.g. an Applied Biosystems (Foster City, CA) model 380B, 392 or 394 DNA/RNA synthesizer, or like instrument. Preferably, phosphoramidite chemistry is employed, e.g. as disclosed in the following references: Beaucage and Iyer, *Tetrahedron*, 48: 2223-2311 (1992); Molko et al, U.S. patent 4,980,460; Koster et al, U.S. patent 4,725,677; Caruthers et al, U.S. patents 4,415,732; 4,458,066; and 4,973,679; and the like. For therapeutic use, nuclease resistant backbones are preferred. Many types of modified oligonucleotides are available that confer nuclease resistance, e.g. phosphorothioate, phosphorodithioate, phosphoramidate, or the like, described in many references, e.g. phosphorothioates: Stec et al, U.S. patent 5,151,510; Hirschbein, U.S. patent 5,166,387; Bergot, U.S. patent 5,183,885; phosphoramidates: Froehler et al, International application PCT/US90/03138; and for a review of additional applicable chemistries: Uhlmann and Peyman (cited above). The length of the antisense oligonucleotides has to be sufficiently large to ensure that specific binding will take place only at the desired target polynucleotide and not at other fortuitous sites. The upper range of the length is determined by several factors, including the inconvenience and expense of synthesizing and purifying oligomers greater than about 30-40 nucleotides in length, the greater tolerance of longer oligonucleotides for mismatches than shorter oligonucleotides, and the like. Preferably, the antisense oligonucleotides of the invention have lengths in the range of about 15 to 40 nucleotides. More preferably, the oligonucleotide moieties have lengths in the range of about 18 to 25 nucleotides.

Primers and probes

Primers and probes of the invention can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang SA et al (*Methods Enzymol* 1979;68:90-98), the phosphodiester method of Brown EL et al (*Methods Enzymol* 1979;68:109-151), the diethylphosphoramidite method of Beaucage et al (*Tetrahedron Lett* 1981, 22: 1859-1862) and the solid support method described in EP 0 707 592, the disclosures of which are incorporated herein by reference in their entireties.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. If desired, the probe may be rendered "non-extendable" in that additional dNTPs

5 cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group.

10 Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label group known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Additional examples include non-radioactive labeling of nucleic acid fragments as described in Urdea et al. (Nucleic Acids Research. 11:4937-4957, 1988) or Sanchez-Pescador et al. (J. Clin. Microbiol. 26(10):1934-1938, 1988). In addition, 15 the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al (Nucleic Acids Symp. Ser. 24:197-200, 1991) or in the European patent No. EP 0225807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either 20 the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the 25 polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a 30 sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR 35 amplification products. They may also be used to detect mismatches in Pep714-encoding genes or

mRNA using other techniques.

Any of the nucleic acids, polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, 5 nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood 10 cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and 15 immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member attached to the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the 20 performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes and other configurations known to those of ordinary skill in the art. The nucleic acids, polynucleotides, primers and probes of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 25 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Any polynucleotide provided herein may be attached in overlapping areas or at random 30 locations on a solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a 35 substrate in different known locations. The knowledge of the precise location of each

polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092, the disclosures of which are incorporated herein by reference in their entireties.

Methods for obtaining variant nucleic acids and polypeptides

In addition to naturally-occurring allelic variants of the Pep714-related peptide sequences that may exist in the population, the skilled artisan will appreciate that changes can be introduced by mutation into the nucleotide sequences coding for Pep714-related peptides, thereby leading to changes in the amino acid sequence of the encoded Pep714-related peptides, with or without altering the functional ability of the Pep714-related peptides.

Several types of variants are contemplated including 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mutated Pep714-related peptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the Pep714-related peptide, such as a leader, a signal or anchor sequence, a sequence which is employed for purification of the Pep714-related peptide, or sequence from a precursor protein. Such variants are deemed to be within the scope of those skilled in the art.

For example, nucleotide substitutions leading to amino acid substitutions can be made in the sequences that do not substantially change the biological activity of the protein. An amino acid residue can be altered from the wild-type sequence encoding a Pep714-related peptide, or a biologically active fragment or homologue thereof without altering the biological activity. In general, amino acid residues that are shared among the Pep714-related peptides of the present invention are predicted to be less amenable to alteration.

In another aspect, the invention pertains to nucleic acid molecules encoding Pep714-related peptides that contain changes in amino acid residues that result in increased biological activity, or a modified biological activity. In another aspect, the invention pertains to nucleic acid molecules encoding Pep714-related peptides that contain changes in amino acid residues that are essential for a Pep714-related biological activity. Such Pep714-related peptides differ in amino acid sequence from SEQ ID NOs:1-6 and display reduced activity, or essentially lack one or more Pep714-related peptide biological activities.

Mutations, substitutions, additions, or deletions can be introduced into any of SEQ ID NOs:1-6, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. For example, conservative amino acid substitutions may be made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a Pep714-related peptide, or a biologically active fragment or homologue thereof may be replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a Pep714-related peptide coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for Pep714-related biological activity to identify mutants that retain activity. Following mutagenesis of the nucleotide encoding one of SEQ ID NOs:1-6, the encoded protein can be expressed recombinantly and the activity of the protein can be determined in any suitable assay, for example, as provided herein.

The invention also provides Pep714-related peptide chimeric or fusion proteins. As used herein, a Pep714-related peptide "chimeric protein" or "fusion protein" comprises a Pep714-related peptide of the invention or fragment therof, operatively linked or fused in frame to a non-PEP714-related peptide sequence. In a preferred embodiment, a Pep714-related peptide fusion protein comprises at least one biologically active portion of a Pep714-related peptide. In another preferred embodiment, a Pep714-related peptide fusion protein comprises at least two biologically active portions of a Pep714-related peptide. For example, in one embodiment, the fusion protein is a GST-Pep714-related peptide fusion protein in which Pep714-related peptide domain sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant Pep714-related peptides. In another embodiment, the fusion protein is a Pep714-related peptide containing a heterologous signal sequence at its N-terminus, for example, to allow for a desired cellular localization in a certain host cell. In yet another embodiment, the fusion is a Pep714-related peptide biologically active fragment and an immunoglobulin molecule. Such fusion proteins are useful, for example, to increase the valency of Pep714-related peptide binding sites. For example, a bivalent Pep714-related peptide binding site may be formed by fusing biologically active Pep714-related peptide fragments to an IgG Fc protein.

The Pep714-related peptide fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Moreover, the Pep714-related peptide fusion proteins of the invention can be used as immunogens to produce anti- Pep714-related peptide antibodies in a subject, to purify Pep714-related peptide ligands and in screening assays to identify molecules which inhibit the interaction of Pep714-related peptide with a target molecule.

Furthermore, isolated fragments of Pep714-related peptides can also be obtained by screening peptides recombinantly produced from the corresponding fragment of the nucleic acid encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, a Pep714-related peptide of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or preferably divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments functioning as agonists or antagonists of a Pep714-related biological activity, for example, by microinjection assays or *in vitro* protein binding assays. In an illustrative embodiment, peptidyl portions of a Pep714-related peptide, such as a Pep714-related peptide target binding region, can be tested for Pep714-related peptide activity by expression as thioredoxin fusion proteins, each of which contains a discrete fragment of the Pep714-related peptide (see, for example, U.S. Patents 5,270,181 and 5,292,646; and PCT publication W094/02502, the disclosures of which are incorporated herein by reference).

The present invention also pertains to variants of Pep714-related peptides which function as either Pep714-related peptide agonists or antagonists. Variants of the Pep714-related peptide can be generated by mutagenesis, e.g., discrete point mutation or truncation of a Pep714-related peptide. An agonist of a Pep714-related peptide can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a Pep714-related peptide. An antagonist of a Pep714-related peptide can inhibit one or more of the activities of the naturally occurring form of the Pep714-related peptide by, for example, competitively inhibiting the association of Pep714-related peptide with a Pep714-related peptide target molecule. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, variants of a Pep714-related peptide which function as either Pep714-related peptide agonists (mimetics) or as Pep714-related peptide antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a Pep714-related peptide for Pep714-related peptide agonist or antagonist activity. In one embodiment, a variegated library of Pep714-related peptide variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of Pep714-related peptide variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a

degenerate set of potential Pep714-related peptide sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of Pep714-related peptide sequences therein. There are a variety of methods which can be used to produce libraries of potential Pep714-related peptide variants from a degenerate 5 oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential Pep714-related peptide sequences.

In addition, libraries of fragments of a Pep714-related peptide coding sequence can be used 10 to generate a variegated population of Pep714-related peptide fragments for screening and subsequent selection of variants of a Pep714-related peptide. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of Pep714-related peptide coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded 15 DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the Pep714-related peptide.

Modified Pep714-related peptides can be used for such purposes as enhancing therapeutic or 20 prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides, when designed to retain at least one activity of the naturally occurring form of the protein, are considered functional equivalents of the Pep714-related peptide described in more detail herein. Such modified peptide can be produced, for instance, by amino acid 25 substitution, deletion, or addition.

Whether a change in the amino acid sequence of a peptide results in a functional Pep714-related peptide homolog can be readily determined by assessing at least one Pep714-related 30 biological activity of the variant peptide. Peptides in which more than one replacement has taken place can readily be tested in the same manner.

This invention further contemplates a method of generating sets of combinatorial mutants of the presently disclosed Pep714-related peptides, as well as truncation and fragmentation mutants, and is especially useful for identifying potential variant sequences which are functional in binding to a Pep714-related peptide target protein but differ from a wild-type form of the protein by, for example, efficacy, potency and/or intracellular half-life. One purpose for screening such 35 combinatorial libraries is, for example, to isolate novel Pep714-related peptide homologs with

altered biological activity when compared with the wild-type protein, or alternatively, possessing novel activities all together. For example, mutagenesis can give rise to Pep714-related peptide homologs which have intracellular half-lives dramatically different than the corresponding wild-type protein. The altered protein can be rendered either more stable or less stable to proteolytic degradation, or cellular processes which result in destruction of, or otherwise inactivation of, a Pep714-related peptide. Such Pep714-related peptide homologs, and the genes which encode them, can be utilized to alter the envelope of expression for a particular recombinant Pep714-related peptide by modulating the half-life of the recombinant protein. For instance, a short half-life can give rise to more transient biological effects associated with a particular recombinant Pep714-related peptide and, when part of an inducible expression system, can allow tighter control of recombinant protein levels within a cell and in circulating plasma. As above, such proteins, and particularly their recombinant nucleic acid constructs, can be used in gene therapy protocols.

In an illustrative embodiment of this method, the amino acid sequences for a population of Pep714-related peptide homologs or other related proteins are aligned, preferably to promote the highest homology possible. Such a population of variants can include, for example, Pep714-related peptide homologs from one or more species, or Pep714-related peptide homologs from the same species but which differ due to mutation. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences. There are many ways by which the library of potential Pep714-related peptide homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be ligated into an appropriate gene for expression. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential Pep714-related peptide sequences. The synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) *Tetrahedron* 393; Itakura et al. (1981) *Recombinant DNA*, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp. 273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos: 5, 223,409, 5,198,346, and 5,096,815). The disclosures of the above references are incorporated herein by reference in their entireties.

Alternatively, other forms of mutagenesis can be utilized to generate a combinatorial library, particularly where no other naturally occurring homologs have yet been sequenced. For example, Pep714-related peptide homologs (both agonist and antagonist forms) can be generated and isolated

from a library by screening using, for example, alanine scanning mutagenesis and the like (Ruf et al. (1994) *Biochemistry* 33:1565-1572; Wang et al. (1994) *J Biol. Chem.* 269:3095-3099; Balint et al. (1993) *Gene* 137:109-118; Grodberg et al. (1993) *Eur. J Biochem.* 218:597-601; Nagashima et al. (1993) *J Biol. Chem.* 268:2888-2892; Lowman et al. (1991) *Biochemistry* 30:10832-10838; and Cunningham et al. (1989) *Science* 244:1081-1085), by linker scanning mutagenesis (Gustin et al. (1993) *Virology* 193:653-660; Brown et al. (1992) *Mol. Cell Biol.* 12:2644 2652; McKnight et al. (1982) *Science* 232:316); by saturation mutagenesis (Meyers et al. (1986) *Science* 232:613); by PCR mutagenesis (Leung et al. (1989) *Method Cell Mol Biol* 1: 1-19); or by random mutagenesis (Miller et al. (1992) *A Short Course in Bacterial Genetics*, CSHL Press, Cold Spring Harbor, NY; and Greener et al. (1994) *Strategies in Mol Biol* 7:32-34, the disclosures of which are incorporated herein by reference in their entireties). A further method exploits automatic protein design to generate protein libraries for screening and optimization of the sequence of a protein of the invention. See, for example, U.S. Patent 6403312, disclosure of which is incorporated herein by reference. Briefly, a primary library is generated using computational processing based on the sequence and structural characteristics of the Pep714-related peptide. Generally speaking, the goal of the computational processing is to determine a set of optimized protein sequences that result in the lowest energy conformation of any possible sequence. However, a plurality of sequences that are not the global minimum may have low energies and be useful. Thus, a primary library comprising a rank ordered list of sequences, generally in terms of theoretical quantitative stability, is generated. These sequences may be used to synthesize or express peptides displaying an extended half-life or stabilized interactions with Pep714-related peptide binding compounds and proteins.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations, as well as for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of Pep714-related peptides. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.

Each of the illustrative assays described below are amenable to high throughput analysis as necessary to screen large numbers of degenerate Pep714-related peptide sequences created by combinatorial mutagenesis techniques. In one screening assay, the candidate gene products are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind a Pep714-related peptide target molecule (for example a modified peptide substrate) via this

gene product is detected in a "panning assay". For instance, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) BioTechnology 9:1370-1371, and Goward et al. (1992) TIBS 18:136 140). In a similar fashion, fluorescently labeled Pep714-related peptide 5 target can be used to score for potentially functional Pep714-related peptide homologs. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence- activated cell sorter.

In an alternate embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be 10 expressed on the surface of infectious phages, thereby conferring two significant benefits. First, since these phages can be applied to affinity matrices at very high concentrations, a large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* 15 filamentous phages M13, fd, and fl are most often used in phage display libraries, as either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al. (1992) 20 PNAS 89:4457 4461, the disclosures of which are incorporated herein by reference in their entireties). In an illustrative embodiment, the recombinant phage antibody system (RPAS, Pharmacia Catalog number 27-9400-01) can be easily modified for use in expressing Pep714-related peptide combinatorial libraries, and the Pep714-related peptide phage library can be panned on immobilized 25 Pep714-related peptide target molecule (glutathione immobilized Pep714-related peptide target-GST fusion proteins or immobilized DNA). Successive rounds of phage amplification and panning can greatly enrich for Pep714-related peptide homologs which retain an ability to bind a Pep714-related peptide target and which can subsequently be screened further for biological activities in automated assays, in order to distinguish between agonists and antagonists.

The invention also provides for identification and reduction to functional minimal size of the 30 Pep714-related peptide functional domains, to generate mimetics, e.g. peptide or non-peptide agents, which are able to disrupt binding of a polypeptide of the present invention with a Pep714-related peptide target molecule. Thus, such mutagenic techniques as described above are also useful to map the determinants of Pep714-related peptides participating in protein-protein interactions involved in, for example, binding to a Pep714-related peptide target protein. To illustrate, the critical residues of 35 a Pep714-related peptide involved in molecular recognition of the Pep714-related peptide target can

be determined and used to generate Pep714-related peptide target-13P-derived peptidomimetics that competitively inhibit binding of the Pep714-related peptide to the Pep714-related peptide target. For instance, non hydrolyzable peptide analogs of such residues can be generated using retro-inverse peptides (e.g., see U.S. Patents 5,116,947 and 5,219,089; and Pallai et al. (1983) *Int J Pept Protein Res* 21:84-92), benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides. Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function (Proceedings of the 9th American Peptide Symposium)* Pierce Chemical Co. Rockland, IL, 1985), P-turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Left* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans 1*: 123 1), and P-aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71, the disclosures of which are incorporated herein by reference in their entireties).

Chemical Manufacture of Pep714-Related Compositions

Peptides of the invention are synthesized by standard techniques (e.g. Stewart and Young, *Solid Phase Peptide Synthesis*, 2nd Ed., Pierce Chemical Company, Rockford, IL, 1984). Preferably, a commercial peptide synthesizer is used, e.g. Applied Biosystems, Inc. (Foster City, CA) model 430A, and polypeptides of the invention may be assembled from multiple, separately synthesized and purified, peptide in a convergent synthesis approach, e.g. Kent et al, U.S. patent 6,184,344 and Dawson and Kent, *Annu. Rev. Biochem.*, 69: 923-960 (2000). Peptides of the invention may be assembled by solid phase synthesis on a cross-linked polystyrene support starting from the carboxyl terminal residue and adding amino acids in a stepwise fashion until the entire peptide has been formed. The following references are guides to the chemistry employed during synthesis: Schnolzer et al, *Int. J. Peptide Protein Res.*, 40: 180-193 (1992); Merrifield, *J. Amer. Chem. Soc.*, Vol. 85, pg. 2149 (1963); Kent et al., pg 185, in *Peptides 1984*, Ragnarsson, Ed. (Almquist and Weksell, Stockholm, 1984); Kent et al., pg. 217 in *Peptide Chemistry 84*, Izumiya, Ed. (Protein Research Foundation, B.H. Osaka, 1985); Merrifield, *Science*, Vol. 232, pgs. 341-347 (1986); Kent, *Ann. Rev. Biochem.*, Vol. 57, pgs. 957-989 (1988), and references cited in these latter two references.

Preferably, chemical synthesis of polypeptides of the invention is carried out by the assembly of peptide fragments by native chemical ligation, as described by Dawson et al, *Science*, 266: 776-779 (1994) and Kent et al, U.S. patent 6,184,344. Briefly, in the approach a first peptide

fragment is provided with an N-terminal cysteine having an unoxidized sulphydryl side chain, and a second peptide fragment is provided with a C-terminal thioester. The unoxidized sulphydryl side chain of the N-terminal cysteine is then condensed with the C-terminal thioester to produce an intermediate peptide fragment which links the first and second peptide fragments with a β -aminothioester bond. The β -aminothioester bond of the intermediate peptide fragment then undergoes an intramolecular rearrangement to produce the peptide fragment product which links the first and second peptide fragments with an amide bond. Preferably, the N-terminal cysteine of the internal fragments is protected from undesired cyclization and/ or concatenation reactions by a cyclic thiazolidine protecting group as described below. Preferably, such cyclic thiazolidine protecting group is a thioprolinyl group.

Peptide fragments having a C-terminal thioester may be produced as described in the following references, which are incorporated by reference: Kent et al, U.S. patent 6,184,344; Tam et al, Proc. Natl. Acad. Sci., 92: 12485-12489 (1995); Blake, Int. J. Peptide Protein Res., 17: 273 (1981); Canne et al, Tetrahedron Letters, 36: 1217-1220 (1995); Hackeng et al, Proc. Natl. Acad. Sci., 94: 7845-7850 (1997); or Hackeng et al, Proc. Natl. Acad. Sci., 96: 10068-10073 (1999). Preferably, the method described by Hackeng et al (1999) is employed. Briefly, peptide fragments are synthesized on a solid phase support (described below) typically on a 0.25 mmol scale by using the in situ neutralization/HBTU activation procedure for Boc chemistry disclosed by Schnolzer et al, Int. J. Peptide Protein Res., 40: 180-193 (1992), which reference is incorporated herein by reference. (HBTU is 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and Boc is tert-butoxycarbonyl). Each synthetic cycle consists of N^{α} -Boc removal by a 1- to 2- minute treatment with neat TFA, a 1-minute DMF flow wash, a 10- to 20-minute coupling time with 1.0 mmol of preactivated Boc-amino acid in the presence of DIEA, and a second DMF flow wash. (TFA is trifluoroacetic acid, DMF is N,N-dimethylformamide, and DIEA is N,N-diisopropylethylamine). N^{α} -Boc-amino acids (1.1 mmol) are preactivated for 3 minutes with 1.0 mmol of HBTU (0.5 M in DMF) in the presence of excess DIEA (3 mmol). After each coupling step, yields are determined by measuring residual free amine with a conventional quantitative ninhydrin assay, e.g. as disclosed in Sarin et al, Anal. Biochem., 117: 147-157 (1981). After coupling of Gln residues, a DCM flow wash is used before and after deprotection by using TFA, to prevent possible high-temperature (TFA/DMF)-catalyzed pyrrolidone formation. After chain assembly is completed, the peptide fragments are deprotected and cleaved from the resin by treatment with anhydrous HF for 1 hour at 0°C with 4% *p*-cresol as a scavenger. The imidazole side-chain 2,4-dinitrophenyl (dnp) protecting groups remain on the His residues because the dnp-removal procedure is incompatible with C-terminal thioester groups. However, dnp is gradually removed by thiols during the ligation reaction. After cleavage, peptide fragments are precipitated

with ice-cold diethylether, dissolved in aqueous acetonitrile, and lyophilized.

Thioester peptide fragments described above are preferably synthesized on a trityl-associated mercaptopropionic acid-leucine (TAMPAL) resin, made as disclosed by Hackeng et al (1999), or comparable protocol. Briefly, N^α-Boc-Leu (4 mmol) is activated with 3.6 mmol of HBTU in the presence of 6 mmol of DIEA and coupled for 16 minutes to 2 mmol of p-methylbenzhydrylamine (MBHA) resin, or the equivalent. Next, 3 mmol of S-trityl mercaptopropionic acid is activated with 2.7 mmol of HBTU in the presence of 6 mmol of DIEA and coupled for 16 minutes to Leu-MBHA resin. The resulting TAMPAL resin can be used as a starting resin for polypeptide-chain assembly after removal of the trityl protecting group with two 1-minute treatments with 3.5% triisopropylsilane and 2.5% H₂O in TFA. The thioester bond can be formed with any desired amino acid by using standard in situ-neutralization peptide coupling protocols for 1 hour, as disclosed in Schnolzer et al (cited above). Treatment of the final peptide fragment with anhydrous HF yields the C-terminal activated mercaptopropionic acid-leucine (MPAL) thioester peptide fragments.

Preferably, thiazolidine-protected thioester peptide fragment intermediates are used in native chemical ligation under conditions as described by Hackeng et al (1999), or like conditions. Briefly, 0.1 M phosphate buffer (pH 8.5) containing 6 M guanidine, 4% (vol/vol) benzylmercaptan, and 4% (vol/vol) thiophenol is added to dry peptides to be ligated, to give a final peptide concentration of 1-3 mM at about pH 7, lowered because of the addition of thiols and TFA from the lyophilized peptide. Preferably, the ligation reaction is performed in a heating block at 37°C and is periodically vortexed to equilibrate the thiol additives. The reaction may be monitored for degree of completion by MALDI-MS or HPLC and electrospray ionization MS.

After a native chemical ligation reaction is completed or stopped, the N-terminal thiazolidine ring of the product is opened by treatment with a cysteine deprotecting agent, such as O-methylhydroxylamine (0.5 M) at pH 3.5-4.5 for 2 hours at 37°C, after which a 10-fold excess of Tris-(2-carboxyethyl)-phosphine is added to the reaction mixture to completely reduce any oxidizing reaction constituents prior to purification of the product by conventional preparative HPLC. Preferably, fractions containing the ligation product are identified by electrospray MS, are pooled, and lyophilized.

After the synthesis is completed and the final product purified, the final polypeptide product may be refolded by conventional techniques, e.g. Creighton, Meth. Enzymol., 107: 305-329 (1984); White, Meth. Enzymol., 11: 481-484 (1967); Wetlaufer, Meth. Enzymol., 107: 301-304 (1984); and the like. Preferably, a final product is refolded by air oxidation by the following, or like: The reduced lyophilized product is dissolved (at about 0.1 mg/mL) in 1 M guanidine hydrochloride (or like chaotropic agent) with 100 mM Tris, 10 mM methionine, at pH 8.6. After gentle overnight

stirring, the re-folded product is isolated by reverse phase HPLC with conventional protocols.

Recombinant Expression Vectors and Host Cells

The polynucleotide sequences described herein can be used in recombinant DNA molecules 5 that direct the expression of the corresponding polypeptides in appropriate host cells. Because of the degeneracy in the genetic code, other DNA sequences may encode the equivalent amino acid sequence, and may be used to clone and express the Pep714-related peptides. Codons preferred by a particular host cell may be selected and substituted into the naturally occurring nucleotide sequences, to increase the rate and/or efficiency of expression. The nucleic acid (e.g., cDNA or 10 genomic DNA) encoding the desired Pep714-related peptide may be inserted into a replicable vector for cloning (amplification of the DNA), or for expression. The polypeptide can be expressed recombinantly in any of a number of expression systems according to methods known in the art (Ausubel, et al., editors, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1990). Appropriate host cells include yeast, bacteria, archebacteria, fungi, and insect and animal 15 cells, including mammalian cells, for example primary cells, including stem cells, including, but not limited to bone marrow stem cells. More specifically, these include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors, and yeast transformed with yeast expression vectors. Also included, are insect cells infected with a recombinant insect virus (such as baculovirus), and mammalian 20 expression systems. The nucleic acid sequence to be expressed may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors 25 containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The Pep714-related peptides of the present invention are produced by culturing a host cell transformed with an expression vector containing a nucleic acid encoding a Pep714-related peptides, under the appropriate conditions to induce or cause expression of the protein. The conditions 30 appropriate for Pep714-related peptides expression will vary with the choice of the expression vector and the host cell, as ascertained by one skilled in the art. For example, the use of constitutive promoters in the expression vector may require routine optimization of host cell growth and proliferation, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the 35 baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection

can be crucial for product yield.

A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, glycosyl, acetyl, phosphate, amide, lipid, carboxyl, acyl, or carbohydrate groups. Post-translational processing, which cleaves a "prepro" form of the protein, may also be important for correct insertion, folding and/or function. By way of example, host cells such as CHO, HeLa, BHK, MDCK, 293, W138, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein. Of particular interest are 5 *Drosophila melanogaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, SF9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, and HeLa cells, fibroblasts, Schwanoma cell lines, immortalized mammalian myeloid and lymphoid cell lines, Jukat cells, 10 human cells and other primary cells.

The nucleic acid encoding a Pep714-related peptide must be "operably linked" by placing it 15 into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, 20 "operably linked" DNA sequences are contiguous, and, in the case of a secretory leader or other polypeptide sequence, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Promoter sequences encode either constitutive or inducible promoters. The promoters may 25 be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention. The expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a prokaryotic host for cloning and 30 amplification. Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2: plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Further, for 35 integrating expression vectors, the expression vector contains at least one sequence homologous to

the host cell genome, and preferably, two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art. In an additional embodiment, a heterologous expression control element may 5 be operably linked with the endogenous gene in the host cell by homologous recombination (described in US Patents 6410266 and 6361972, disclosures of which are hereby incorporated by reference in their entireties). This technique allows one to regulate expression to a desired level with a chosen control element while ensuring proper processing and modification of Pep714-related peptide endogenously expressed by the host cell. Useful heterologous expression control elements 10 include but are not limited to CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma Virus (RSV), and metallothionein promoters.

Preferably, the expression vector contains a selectable marker gene to allow the selection of 15 transformed host cells. Selection genes are well known in the art and will vary with the host cell used. Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available for from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.

20 Host cells transformed with a nucleotide sequence encoding a Pep714-related peptide may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides encoding the Pep714-related 25 peptides can be designed with signal sequences which direct secretion of the Pep714-related peptides through a prokaryotic or eukaryotic cell membrane. The desired Pep714-related peptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence 30 may be a component of the vector, or it may be a part of the Pep714-related peptides-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* a-factor leaders, the latter described in 35 U.S. Pat. No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP

362,179 published Apr. 4, 1990), or the signal described in WO 90113646 published Nov. 15, 1990.

In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders. According to the expression system selected, the coding sequence is

5 inserted into an appropriate vector, which in turn may require the presence of certain characteristic "control elements" or "regulatory sequences." Appropriate constructs are known generally in the art (Ausubel, et al., 1990) and, in many cases, are available from commercial suppliers such as Invitrogen (San Diego, Calif.), Stratagene (La Jolla, Calif.), Gibco BRL (Rockville, Md.) or Clontech (Palo Alto, Calif.).

10

Expression in Bacterial Systems.

Transformation of bacterial cells may be achieved using an inducible promoter such as the hybrid lacZ promoter of the "BLUESCRIPT" Phagemid (Stratagene) or "pSPORT1" (Gibco BRL).

In addition, a number of expression vectors may be selected for use in bacterial cells to produce

15 cleavable fusion proteins that can be easily detected and/or purified, including, but not limited to "BLUESCRIPT" (a-galactosidase; Stratagene) or pGEX (glutathione S-transferase; Promega, Madison, Wis.). A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of the coding sequence of the Pep714-related peptide into mRNA. A bacterial promoter has a transcription initiation region

20 which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences.

Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan.

15 Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tat promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. An efficient ribosome binding site is also desirable. The expression vector may also

30 include a signal peptide sequence that provides for secretion of the Pep714-related peptide in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial

35 expression vector may also include a selectable marker gene to allow for the selection of bacterial

strains that have been transformed. Suitable selection genes include drug resistance genes such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. When large quantities of a Pep714-related peptide are needed, e.g., for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the Pep714-related peptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; PIN vectors (Van Heeke & Schuster *J Biol Chem* 264:5503-5509 1989); PET vectors (Novagen, Madison Wis.); and the like. Expression vectors for bacteria include the various components set forth above, and are well known in the art. Examples include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others. Bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride mediated transfection, electroporation, and others.

Expression in Yeast.

Yeast expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillevimondii* and *P pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*. Examples of suitable promoters for use in yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073 (1980)) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149 (1968); Holland, *Biochemistry* 17:4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, alpha factor, the ADH2IGAPDH promoter, glucokinase alcohol oxidase, and PGH. (See, for example, Ausubel, et al., 1990; Grant et al., *Methods in Enzymology* 153:516-544, (1987)). Other yeast promoters, which are inducible have the additional advantage of transcription controlled by growth conditions, include the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast selectable markers include ADE2, HIS4, LEU2, TRP1, and ALG7, which confer resistance to tunicamycin; the neomycin phosphotransferase gene, which confers resistance to G418; and the CUP1 gene, which

allows yeast to grow in the presence of copper ions. Yeast expression vectors can be constructed for intracellular production or secretion of Pep714-related peptides from the DNA encoding the Pep714-related peptides of interest. For example, a selected signal peptide and the appropriate constitutive or inducible promoter may be inserted into suitable restriction sites in the selected plasmid for direct 5 intracellular expression of the Pep714-related peptide. For secretion of the Pep714-related peptides, DNA encoding the Pep714-related peptide can be cloned into the selected plasmid, together with DNA encoding the promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (as needed), for expression of the Pep714-related peptide. Yeast cells, can then be transformed with the expression plasmids described above, and cultured in an appropriate 10 fermentation media. The protein produced by such transformed yeast can then be concentrated by precipitation with 10% trichloroacetic acid and analyzed following separation by SDS-PAGE and staining of the gels with Coomassie Blue stain. The recombinant Pep714-related peptides can subsequently be isolated and purified from the fermentation medium by techniques known to those 15 of skill in the art.

15

Expression in Mammalian Systems.

The Pep714-related peptides may be expressed in mammalian cells. Mammalian expression systems are known in the art, and include retroviral vector mediated expression systems. Mammalian host cells may be transformed with any of a number of different viral-based expression 20 systems, such as adenovirus, where the coding region can be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome results in a viable virus capable of expression of the polypeptide of interest in infected host cells. A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and 25 PCT/US97/101048. Suitable mammalian expression vectors contain a mammalian promoter which is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence for Pep714-related peptide into mRNA. A promoter will have a transcription-initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation 30 site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the 35 viral genes are often highly expressed and have a broad host range. Examples include promoters

obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211, 504 published Jul. 5, 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and 5 from heat-shock promoters, provided such promoters are compatible with the host cell systems. Transcription of DNA encoding a Pep714-related peptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and 10 insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer is preferably located at a site 5' from the promoter. In general, the transcription termination and polyadenylation 15 sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40. Long term, high-yield production of recombinant proteins can be effected in a stable expression 20 system. Expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene may be used for this purpose. Appropriate vectors containing selectable markers for use in mammalian cells are readily available commercially and are known to persons skilled in the art. Examples of such selectable markers include, but are not limited to herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase for use in tk- or hprt-cells, respectively. The methods of introducing exogenous nucleic acid into mammalian hosts, as well as 25 other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Pep714-related peptides can be purified from culture supernatants of mammalian cells 30 transiently transfected or stably transformed by an expression vector carrying a Pep714-related peptide-encoding sequence. Preferably, Pep714-related peptide is purified from culture supernatants of COS 7 cells transiently transfected by the pcD expression vector. Transfection of COS 7 cells with pcD proceeds as follows: One day prior to transfection, approximately 10^6 COS 7 monkey cells are seeded onto individual 100 mm plates in Dulbecco's modified Eagle medium (DME) 35 containing 10% fetal calf serum and 2 mM glutamine. To perform the transfection, the medium is

aspirated from each plate and replaced with 4 ml of DME containing 50 mM Tris.HCl pH 7.4, 400 mg/ml DEAE-Dextran and 50 µg of plasmid DNA. The plates are incubated for four hours at 37°C, then the DNA-containing medium is removed, and the plates are washed twice with 5 ml of serum-free DME. DME is added back to the plates which are then incubated for an additional 3 hrs at 37°C. The plates are washed once with DME, after which DME containing 4% fetal calf serum, 2 mM glutamine, penicillin (100 U/L) and streptomycin (100 µg/L) at standard concentrations is added. The cells are then incubated for 72 hrs at 37°C, after which the growth medium is collected for purification of Pep714-related peptide. Alternatively, transfection can be accomplished by electroporation as described in the examples. Plasmid DNA for the transfections is obtained by growing pcD(SR α), or like expression vector, containing the Pep714-related peptide-encoding cDNA insert in *E. coli* MC1061, described by Casadaban and Cohen, *J. Mol. Biol.*, Vol. 138, pgs. 179-207 (1980), or like organism. The plasmid DNA is isolated from the cultures by standard techniques, e.g. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition (Cold Spring Harbor Laboratory, New York, 1989) or Ausubel et al (1990, cited above).

15

Expression in Insect Cells.

Pep714-related peptides may also be produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art. In one such system, the Pep714-related peptide-encoding DNA is fused upstream of an epitope tag contained within a baculovirus expression vector. *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* S9 cells or in *Trichoplusia* larvae. The Pep714-related peptide-encoding sequence is cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of a Pep714-related peptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which the Pep714-related peptide is expressed (Smith et al., *J. Wol.* 46:584 (1994); Engelhard E K et al., *Proc. Nat. Acad. Sci.* 91:3224-3227 (1994)). Suitable epitope tags for fusion to the Pep714-related peptide-encoding DNA include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including commercially available plasmids such as pVL1393 (Novagen). Briefly, the Pep714-related peptide-encoding DNA or the desired portion of the Pep714-related peptide-encoding DNA is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking restriction sites. The PCR product is then digested with the selected restriction enzymes and subcloned into an expression vector. Recombinant baculovirus is generated by co-transfected the above plasmid and BaculoGold™ virus DNA.

(Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL), or other methods known to those of skill in the art. Virus is produced by day 4-5 of culture in Sf9 cells at 28°C., and used for further amplifications. Procedures are performed as further described in O'Reilley et al., *BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL*, Oxford University Press (1994). Extracts may be prepared from recombinant virus-infected Sf9 cells as described in Rupert et al., *Nature* 362:175-179 (1993). Alternatively, expressed epitope-tagged Pep714-related peptides can be purified by affinity chromatography, or for example, purification of an IgG tagged (or Fc tagged) Pep714-related peptide can be performed using chromatography techniques, including Protein A or protein G column chromatography.

Evaluation of Gene Expression.

Gene expression may be evaluated in a sample directly, for example, by standard techniques known to those of skill in the art, e.g., Northern blotting to determine the transcription of mRNA, dot blotting (DNA or RNA), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be used in assays for detection of polypeptides, nucleic acids, such as specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Such antibodies may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. Gene expression, alternatively, may be measured by immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to directly evaluate the expression of a Pep714-related peptide, polypeptide, or polynucleotide. Antibodies useful for such immunological assays may be either monoclonal or polyclonal, and may be prepared against a native sequence Pep714-related peptide. Protein levels may also be detected by mass spectrometry. A further method of protein detection is with protein chips.

Purification of Expressed Protein.

Expressed Pep714-related peptides may be purified or isolated after expression, using any of a variety of methods known to those skilled in the art. The appropriate technique will vary depending upon what other components are present in the sample. Contaminant components that are removed by isolation or purification are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other solutes. The purification step(s) selected will depend, for example, on the nature of the production process used and the particular Pep714-related peptide produced. As Pep714-related peptides are secreted, they

may be recovered from culture medium. Alternatively, the Pep714-related peptides or proteins may be recovered from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Alternatively, cells employed in expression of Pep714-related peptides can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or by use of cell lysing agents. Exemplary purification methods include, but are not limited to, ion-exchange column chromatography; chromatography using silica gel or a cation-exchange resin such as DEAE; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; chromatography using metal chelating columns to bind epitope-tagged forms of the Pep714-related peptide; ethanol precipitation; reverse phase HPLC; chromatofocusing; SDS-PAGE; and ammonium sulfate precipitation. Ordinarily, an isolated Pep714-related peptide will be prepared by at least one purification step. For example, the Pep714-related peptide may be purified using a standard anti-Pep714-related peptide antibody column. Ultrafiltration and dialysis techniques, in conjunction with protein concentration, are also useful (see, for example, Scopes, R., *PROTEIN PURIFICATION*, Springer-Verlag, New York, N.Y., 1982). The degree of purification necessary will vary depending on the use of the Pep714-related peptides. In some instances no purification will be necessary. Once expressed and purified as needed, the Pep714-related peptides and nucleic acids of the present invention are useful in a number of applications, as detailed herein.

20 *Transgenic animals*

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which Pep714-related peptides-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous Pep714-related peptides sequences have been introduced into their genome or homologous recombinant animals in which endogenous Pep714-related peptides sequences have been altered. Such animals are useful for studying the function and/or activity of a Pep714-related peptide or fragment thereof and for identifying and/or evaluating modulators of Pep714-related biological activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal include a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a

mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a Pep714-related peptide-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The Pep714-related peptide cDNA sequence or a fragment thereof can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human Pep714 gene, such as from mouse or rat, can be used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to a Pep714-related peptide transgene to direct expression of a Pep714-related peptide to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986, the disclosure of which is incorporated herein by reference in its entirety). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of a Pep714-related peptides transgene in its genome and/or expression of Pep714-related peptides mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a Pep714-related peptide can further be bred to other transgenic animals carrying other transgenes.

To create an animal in which a desired nucleic acid has been introduced into the genome via homologous recombination, a vector is prepared which contains at least a portion of a Pep714 gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the Pep714 gene. The Pep714 gene can be a human gene, but more preferably, is a non-human homologue of a human Pep714 gene (e.g., a cDNA isolated by stringent hybridization with a nucleotide sequence coding for a Pep714-related peptide). For example, a mouse Pep714 gene can be used to construct a homologous recombination vector suitable for altering an endogenous gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous Pep714 gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous Pep714 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be

altered to thereby alter the expression of the endogenous Pep714-related peptide). In the homologous recombination vector, the altered portion of the Pep714 gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the Pep714 gene to allow for homologous recombination to occur between the exogenous sequence carried by the vector and an endogenous gene in an

5 embryonic stem cell. The additional flanking nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K. R. and Capecchi, M. R. (1987) *Cell* 51:503, the disclosure of which is incorporated herein by reference in its entirety, for a description of homologous recombination vectors). The vector is introduced into an
10 embryonic stem cell line (e.g., by electroporation) and cells in which the introduced Pep714 gene has homologously recombined with the endogenous gene are selected (see e.g., Li, E. et al. (1992) *Cell* 69:915, the disclosure of which is incorporated herein by reference in its entirety). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells. A Practical Approach*, E. J.
15 Robertson, ed. (IRL, Oxford, 1987) pp. 113-152, the disclosure of which is incorporated herein by reference in its entirety). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for
20 constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al., the disclosures of which are incorporated herein by reference in their entireties.

25 In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. (1992) *PNAS* 89:6232-6236, the disclosure of which is incorporated herein by reference in its entirety. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355, the disclosure of which is incorporated herein by reference in its entirety). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing
30 a transgene encoding a selected protein and the other containing a transgene encoding a
35

recombinase.

Assessing Pep714-related polypeptides activity

It will be appreciated that the invention further provides methods of testing the activity of, or

5 obtaining, functional fragments and variants of Pep714-related peptides. Such methods involve providing a variant or modified Pep714-related peptide, or Pep714-related nucleic acid and assessing whether a polypeptide encoded thereby displays a Pep714-related biological activity of the invention. Encompassed is thus a method of assessing the function of a Pep714-related peptide comprising: (a) providing a Pep714-related peptide, or a biologically active fragment or homologue thereof; and (b) testing said Pep714-related peptide, or a biologically active fragment or homologue thereof for a Pep714-related biological activity. Any suitable format may be used, including cell free, cell-based and in vivo formats. For example, said assay may comprise expressing a Pep714-related nucleic acid in a host cell, and observing Pep714-related activity in said cell and other affected cells. In another example, a Pep714-related peptide, or a biologically active fragment or homologue thereof is contacted with a cell, and a Pep714-related biological activity is observed.

10 A Pep714-related biological activity may be any activity as described herein, such as (1) forming intermolecular amino acid side chain interactions such as hydrogen, amide, or disulfide links; (2) forming secondary and/or tertiary structures, preferably cyclic structures; antigenicity, or the ability to bind an anti-Pep714-related peptide specific antibody; (4) immunogenicity, or the ability to generate an anti-Pep714-related peptide specific antibody; (5) antimicrobial activity; (6) antiviral activity (e.g., prevention of virus- host cell interactions); (7) mediating levels of a Pep714-related peptide substrate protein; (8) mediating cell proliferation or cell cycle; or (9) interacting with a Pep714-related target molecule, preferably a protein e.g. a substrate protein or protein similar to a substrate, such as gp160, CXCR4, CCR5, CD4 gp120, etc.

15 Pep714-related biological activity can be assayed by any suitable method known in the art. Antigenicity and immunogenicity may be detected, for example, as described in the sections titled "Anti Pep714-related peptide antibodies" and "Uses of Pep714-related peptide antibodies." Circulation in blood plasma may be detected as described in "Diagnostic and Prognostic Uses." Interaction with a Pep714-related peptide target molecule may be detected according to any of the methods described herein, for example, in the section titled "Drug Screening Assays."

20 Structural determinations are preferably made by NMR spectroscopy, as exemplified in Frechet, D., et al. *Biochemistry*, 1994 Jan 11;33(1):42-50 and Constantine K.L., et al., *J Biomol NMR* (1995) 5:271-86, disclosures of which are hereby incorporated by reference in their entireties. In addition, molecular modeling programs are useful for predicting structure. Exemplary programs used in the present invention include Rosetta 1.2 (Bonneau, R., et al. (2001), *Proteins, Suppl* 5, 119-

126) and ICM v2.8.215 with a biased probability Monte Carlo method (Abagyan, R.A. and Totrov, M.M. *J Mol Biol* 235:983-1002 (1994)).

Assays for determining antimicrobial activity include but are not limited to: Radial Diffusion Assays, Microbroth Dilution Assays, Modified NCCLS (National Committee for Clinical Standards)

5 Minimum Inhibitory Concentration Assays, and Kinetic Bactericidal Assays (see US Patent 5,916,872, disclosure of which is incorporated in its entirety).

Assays for detecting antiviral activity include but are not limited to cell fusion assays and the XTT-tetrazolium anti-HIV assay (Lin, et al., *Antimicrob Agents Chemother.* (1996) 40:133-8; Gustafson et al., *J. Med. Chem.* 35, 1978-1986, 1992; Weislow, *Journal of the National Cancer Institute*, 81(8),

10 577-586 (1989); and Gulakowski, *J Virological Methods*, 33, 87-100, (1991), disclosures of which are hereby incorporated by reference in their entireties). In addition, *in vitro* assays that detect Pep714-related peptide binding to viral envelope target proteins (e.g., gp160, CXCR4, CCR5, CD4, gp120, etc.) may be designed as exemplified in Gulakowski et al.(1991), *supra*. These assays detect binding, recognition, or integration of viral particles to host cells and are useful to determine the 15 level of Pep714-related peptide activity, when compared to a negative control. Any such method may be designed or optimized according to methods common to the art. The results may be confirmed by, for example, ultrafiltration experiments and dot-blot assays.

Anti-Pep714-related antibodies

20 The present invention provides antibodies and binding compositions specific for Pep714-related peptides. Such antibodies and binding compositions include polyclonal antibodies, monoclonal antibodies, Fab and single chain Fv fragments thereof, bispecific antibodies, heteroconjugates, humanized antibodies, and the like. Such antibodies and binding compositions may be produced in a variety of ways, including hybridoma cultures, recombinant expression in 25 bacteria or mammalian cell cultures, recombinant expression in transgenic animals, and the like. There is abundant guidance in the literature for selecting a particular production methodology, e.g. Chadd and Chamow, *Curr. Opin. Biotechnol.*, 12: 188-194 (2001).

The choice of manufacturing methodology depends on several factors including the antibody structure desired, the importance of carbohydrate moieties on the antibodies, ease of culturing and 30 purification, cost, and the like. Many different antibody structures may be generated using standard expression technology, including full-length antibodies, antibody fragments, such as Fab and Fv fragments, as well as chimeric antibodies comprising components from different species. Antibody fragments of small size, such as Fab and Fv fragments, having no effector functions and limited pharmokinetic activity may be generated in a bacterial expression system. Single chain Fv 35 fragments are highly selective for *in vivo* tumors, show good tumor penetration and low

immunogenicity, and are cleared rapidly from the blood, e.g. Freyre et al, *J. Biotechnol.*, 76: 157-163 (2000). Thus, such molecules are desirable for radioimmunodetection and in situ radiotherapy. Whenever pharmacokinetic activity in the form of increased half-life is required for therapeutic purposes, then full-length antibodies are preferable. For example, immunoglobulin G (IgG) the molecule may be one of four subclasses: $\gamma 1$, $\gamma 2$, $\gamma 3$, or $\gamma 4$. If a full-length antibody with effector function is required, then IgG subclasses $\gamma 1$ or $\gamma 3$ are preferred, and IgG subclass $\gamma 1$ is most preferred. The $\gamma 1$ and $\gamma 3$ subclasses exhibit potent effector function, complement activation, and promote antibody-dependent cell-mediated cytotoxicity through interaction with specific Fc receptors, e.g. Raju et al, *Glycobiology*, 10: 477-486 (2000); Lund et al, *J. Immunol.*, 147: 2657-2662 (1991).

Polyclonal Antibodies.

The anti-Pep714-related antibodies of the present invention may be polyclonal antibodies. Such polyclonal antibodies can be produced in a mammal, for example, following one or more 15 injections of an immunizing agent, and preferably, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected into the mammal by a series of subcutaneous or intraperitoneal injections. The immunizing agent may include Pep714-related peptides or a fusion protein thereof. It may be useful to conjugate the antigen to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet 20 hemocyanin (KLH), methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Adjuvants include, for example, Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicoryno-mycolate). The immunization protocol may be determined by one skilled in the art based on standard protocols or by routine experimentation.

25 Alternatively, a crude protein preparation which has been enriched for a Pep714-related peptide or a portion thereof can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies are purified by immunoaffinity chromatography.

30 Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate and excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and 35 Walker (1987), the disclosure of which is incorporated herein by reference in its entirety. An

effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. *J. Clin. Endocrinol. Metab.* 33:988-991(1971), the disclosure of which is incorporated by reference in its entirety. Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against 5 known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12: M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as 10 described, for example, by Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D. C. (1980).

Monoclonal Antibodies.

Alternatively, the anti-Pep714-related antibodies may be monoclonal antibodies.

Monoclonal antibodies may be produced by hybridomas, wherein a mouse, hamster, or other 15 appropriate host animal, is immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent, e.g. Kohler and Milstein, *Nature* 256:495 (1975). The immunizing agent will typically include the Pep714-related peptides or a fusion protein thereof and optionally a carrier. Alternatively, the lymphocytes may be immunized *in vitro*. Generally, spleen cells or lymph node cells are used if non- 20 human mammalian sources are desired, or peripheral blood lymphocytes ("PBLs") are used if cells of human origin. The lymphocytes are fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to produce a hybridoma cell, e.g. Goding, *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE*, Academic Press, pp. 59-103 (1986); Liddell and Cryer, *A Practical Guide to Monoclonal Antibodies* (John Wiley & Sons, New York, 1991); Malik 25 and Lillenj, Editors, *Antibody Techniques* (Academic Press, New York, 1994). In general, immortalized cell lines are transformed mammalian cells, for example, myeloma cells of rat, mouse, bovine or human origin. The hybridoma cells are cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine 30 phosphoribosyl transferase (HGPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT), substances which prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level production of antibody, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine or human myeloma lines, which can be obtained, for example, 35 from the American Type Culture Collection (ATCC), Rockville, MD. Human myeloma and mouse-

human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies, e.g. Kozbor, *J. Immunol.* 133:3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, Marcel Dekker, Inc., New York, pp. 51-63 (1987).

The culture medium (supernatant) in which the hybridoma cells are cultured can be assayed 5 for the presence of monoclonal antibodies directed against a Pep714-related peptide. Preferably, the binding specificity of monoclonal antibodies present in the hybridoma supernatant is determined by immunoprecipitation or by an in vitro binding assay, such as radio- immunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Appropriate techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard 10 analysis of Munson and Pollard, *Anal. Biochem.* 107:220 (1980). After the desired antibody-producing hybridoma cells are identified, the cells may be cloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the 15 hybridoma cells may be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by selected clones may be isolated or purified from the culture medium or ascites fluid by immunoglobulin purification procedures routinely used by those of skill in the art such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those 20 described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be isolated from the Pep714-related peptides-specific hybridoma cells and sequenced, e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies. Once isolated, the DNA may be inserted into an expression vector, which is then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) 25 cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for the human heavy and light chain constant domains for the homologous murine sequences (Morrison et al., *Proc. Nat. Acad. Sci.* 81:6851-6855 (1984); Neuberger et al., *Nature* 312:604-608 (1984); Takeda et al., *Nature* 314:452-454 (1985)), or 30 by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. The non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. The antibodies may also be monovalent antibodies. Methods for preparing monovalent antibodies 35 are well known in the art. For example, in vitro methods are suitable for preparing monovalent

antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

Antibodies and antibody fragments characteristic of hybridomas of the invention can also be produced by recombinant means by extracting messenger RNA, constructing a cDNA library, and selecting clones which encode segments of the antibody molecule. The following are exemplary references disclosing recombinant techniques for producing antibodies: Wall et al., Nucleic Acids Research, Vol. 5, pgs. 3113-3128 (1978); Zakut et al., Nucleic Acids Research, Vol. 8, pgs. 3591-3601 (1980); Cabilly et al., Proc. Natl. Acad. Sci., Vol. 81, pgs. 3273-3277 (1984); Boss et al., Nucleic Acids Research, Vol. 12, pgs. 3791-3806 (1984); Amster et al., Nucleic Acids Research, Vol. 8, pgs. 2055-2065 (1980); Moore et al., U.S. Patent 4,642,334; Skerra et al., Science, Vol. 240, pgs. 1038-1041 (1988); Huse et al., Science, Vol. 246, pgs. 1275-1281 (1989); and U.S. patents 6,054,297; 5,530,101; 4,816,567; 5,750,105; and 5,648,237; which patents are incorporated by reference. In particular, such techniques can be used to produce interspecific monoclonal antibodies, wherein the binding region of one species is combined with non-binding region of the antibody of another species to reduce immunogenicity, e.g. Liu et al., Proc. Natl. Acad. Sci., Vol. 84, pgs. 3439-3443 (1987), and patents 6,054,297 and 5,530,101. Preferably, recombinantly produced Fab and Fv fragments are expressed in bacterial host systems. Preferably, full-length antibodies are produced by mammalian cell culture techniques. More preferably, full-length antibodies are expressed in Chinese Hampster Ovary (CHO) cells or NSO cells.

Both polyclonal and monoclonal antibodies can be screened by ELISA. As in other solid phase immunoassays, the test is based on the tendency of macromolecules to adsorb nonspecifically to plastic. The irreversibility of this reaction, without loss of immunological activity, allows the formation of antigen-antibody complexes with a simple separation of such complexes from unbound material. To titrate antipeptide serum, peptide conjugated to a carrier different from that used in immunization is adsorbed to the wells of a 96-well microtiter plate. The adsorbed antigen is then allowed to react in the wells with dilutions of anti-peptide serum. Unbound antibody is washed away, and the remaining antigen-antibody complexes are allowed to react with antibody specific for the IgG of the immunized animal. The second antibody is conjugated to an enzyme such as alkaline phosphatase. A visible colored reaction product produced when the enzyme substrate is added indicates which wells have bound antipeptide antibodies. The use of spectrophotometer readings allows better quantification of the amount of peptide-specific antibody bound. High-titer antisera yield a linear titration curve between 10^{-3} and 10^{-5} dilutions.

Pep714-related peptide carriers.

The invention includes immunogens derived from Pep714-related peptides, and

immunogens comprising conjugates between carriers and peptides of the invention. The term immunogen as used herein refers to a substance which is capable of causing an immune response. The term carrier as used herein refers to any substance which when chemically conjugated to a peptide of the invention permits a host organism immunized with the resulting conjugate to generate antibodies specific for the conjugated peptide. Carriers include red blood cells, bacteriophages, proteins, or synthetic particles such as agarose beads. Preferably, carriers are proteins, such as serum albumin, gamma-globulin, keyhole limpet hemocyanin, thyroglobulin, ovalbumin, fibrinogen, or the like.

The general technique of linking synthetic peptides to a carrier is described in several references, e.g. Walter and Doolittle, "Antibodies Against Synthetic Peptides," in Setlow et al., eds., Genetic Engineering, Vol. 5, pgs. 61-91 (Plenum Press, N.Y., 1983); Green et al. Cell, Vol. 28, pgs. 477-487 (1982); Lerner et al., Proc. Natl. Acad. Sci., Vol. 78, pgs. 3403-3407 (1981); Shimizu et al., U.S. Patent 4,474,754; and Ganfield et al., U.S. Patent 4,311,639. Accordingly, these references are incorporated by reference. Also, techniques employed to link haptens to carriers are essentially the same as the above-referenced techniques, e.g. chapter 20 in Practice and Theory of Enzyme Immunoassays (Elsevier, New York, 1985). The four most commonly used schemes for attaching a peptide to a carrier are (1) glutaraldehyde for amino coupling, e.g. as disclosed by Kagan and Glick, in Jaffe and Behrman, eds. Methods of Hormone Radioimmunoassay, pgs. 328-329 (Academic Press, N.Y., 1979), and Walter et al. Proc. Natl. Acad. Sci., Vol. 77, pgs. 5197-5200 (1980); (2) water-soluble carbodiimides for carboxyl to amino coupling, e.g. as disclosed by Hoare et al., J. Biol. Chem., Vol. 242, pgs. 2447-2453 (1967); (3) bis-diazobenzidine (DBD) for tyrosine to tyrosine sidechain coupling, e.g. as disclosed by Bassiri et al., pgs. 46-47, in Jaffe and Behrman, eds. (cited above), and Walter et al. (cited above); and (4) maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) for coupling cysteine (or other sulfhydryls) to amino groups, e.g. as disclosed by Kitagawa et al., J. Biochem. (Tokyo), Vol. 79, pgs. 233-239 (1976), and Lerner et al. (cited above). A general rule for selecting an appropriate method for coupling a given peptide to a protein carrier can be stated as follows: the group involved in attachment should occur only once in the sequence, preferably at the appropriate end of the segment. For example, BDB should not be used if a tyrosine residue occurs in the main part of a sequence chosen for its potentially antigenic character. Similarly, centrally located lysines rule out the glutaraldehyde method, and the occurrences of aspartic and glutamic acids frequently exclude the carbodiimide approach. On the other hand, suitable residues can be positioned at either end of chosen sequence segment as attachment sites, whether or not they occur in the "native" protein sequence. Internal segments, unlike the amino and carboxy termini, will differ significantly at the "unattached end" from the same sequence as it is found in the native protein where the polypeptide backbone is continuous. The problem can be

remedied, to a degree, by acetylating the α -amino group and then attaching the peptide by way of its carboxy terminus. The coupling efficiency to the carrier protein is conveniently measured by using a radioactively labeled peptide, prepared either by using a radioactive amino acid for one step of the synthesis or by labeling the completed peptide by the iodination of a tyrosine residue. The presence 5 of tyrosine in the peptide also allows one to set up a sensitive radioimmune assay, if desirable. Therefore, tyrosine can be introduced as a terminal residue if it is not part of the peptide sequence defined by the native polypeptide.

Preferred carriers are proteins, and preferred protein carriers include bovine serum albumin, myoglobin, ovalbumin (OVA), keyhole limpet hemocyanin (KLH), or the like. Peptides can be 10 linked to KLH through cysteines by MBS as disclosed by Liu et al., *Biochemistry*, Vol. 18, pgs. 690-697 (1979). The peptides are dissolved in phosphate-buffered saline (pH 7.5), 0.1 M sodium borate buffer (pH 9.0) or 1.0 M sodium acetate buffer (pH 4.0). The pH for the dissolution of the peptide is chosen to optimize peptide solubility. The content of free cysteine for soluble peptides is determined by Ellman's method, Ellman, *Arch. Biochem. Biophys.*, Vol. 82, pg. 7077 (1959). For each peptide, 15 4 mg KLH in 0.25 ml of 10 mM sodium phosphate buffer (pH 7.2) is reacted with 0.7 mg MBS (dissolved in dimethyl formamide) and stirred for 30 min at room temperature. The MBS is added dropwise to ensure that the local concentration of formamide is not too high, as KLH is insoluble in >30% formamide. The reaction product, KLH-MBS, is then passed through Sephadex G-25 20 equilibrated with 50 mM sodium phosphate buffer (pH 6.0) to remove free MBS, KLH recovery from peak fractions of the column eluate (monitored by OD280) is estimated to be approximately 80%. KLH-MBS is then reacted with 5 mg peptide dissolved 25 in 1 ml of the chosen buffer. The pH is adjusted to 7-7.5 and the reaction is stirred for 3 hr at room temperature. Coupling efficiency is monitored with radioactive peptide by dialysis of a sample of the conjugate against phosphate-buffered saline, and ranged from 8% to 60%. Once the peptide-carrier conjugate is available 25 polyclonal or monoclonal antibodies are produced by standard techniques, e.g. as disclosed by Campbell, *Monoclonal Antibody Technology* (Elsevier, New York, 1984); Hurrell, ed. *Monoclonal Hybridoma Antibodies: Techniques and Applications* (CRC Press, Boca Raton, FL, 1982); Schreier et al. *Hybridoma Techniques* (Cold Spring Harbor Laboratory, New York, 1980); U.S. Patent 4,562,003; or the like. In particular, U.S. Patent 4,562,003 is incorporated by reference.

30

Humanized Antibodies.

The anti-Pep714-related antibodies of the invention may further comprise humanized antibodies or human antibodies. The term "humanized antibody" refers to humanized forms of non-human (e.g., murine) antibodies that are chimeric antibodies, immunoglobulin chains or fragments 35 thereof (such as Fv, Fab, Fab', F(ab'), or other antigen-binding partial sequences of antibodies)

which contain some portion of the sequence derived from non-human antibody. Humanized antibodies include human immunoglobulins in which residues from a complementary determining region (CDR) of the human immunoglobulin are replaced by residues from a CDR of a non-human species such as mouse, rat or rabbit having the desired binding specificity, affinity and capacity. In general, the humanized antibody will comprise substantially all of at least one, and generally two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., *Nature* 321:522-525 (1986) and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992)). Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acids introduced into it from a source which is non-human in order to more closely resemble a human antibody, while still retaining the original binding activity of the antibody. Methods for humanization of antibodies are further detailed in Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-327 (1988); and Verhoeyen et al., *Science* 239:1534-1536 (1988). Such "humanized" antibodies are chimeric antibodies in that substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.

20 *Heteroconjugate Antibodies.*

Heteroconjugate antibodies which comprise two covalently joined antibodies, are also within the scope of the present invention. Heteroconjugate antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be prepared using a disulfide exchange reaction or by forming a thioether bond.

25

Bispecific Antibodies.

Bispecific antibodies have binding specificities for at least two different antigens. Such antibodies are monoclonal, and preferably human or humanized. One of the binding specificities of a bispecific antibody of the present invention is for a Pep714-related peptides, and the other one is preferably for a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art, and in general, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs in hybridoma cells, where the two heavy chains have different specificities, e.g. Milstein and Cuello, *Nature* 305:537-539 (1983). Given that the random assortment of immunoglobulin heavy and light chains results in production of potentially ten different antibody molecules by the hybridomas, purification

of the correct molecule usually requires some sort of affinity purification, e.g. affinity chromatography.

Uses of Pep714-related antibodies

5 Pep714-related antibodies may be used as functional antagonists. Preferably, such antibodies are specific for Pep714-related peptides. More preferably, the antagonists of the invention comprise fragments or binding compositions specific for Pep714-related peptides. As used herein, the term "heavy chain variable region" means a polypeptide (1) which is from 110 to 125 amino acids in length, and (2) whose amino acid sequence corresponds to that of a heavy chain 10 of an antibody of the invention, starting from the heavy chain's N-terminal amino acid. Likewise, the term "light chain variable region" means a polypeptide (1) which is from 95 to 115 amino acids in length, and (2) whose amino acid sequence corresponds to that of a light chain of an antibody of the invention, starting from the light chain's N-terminal amino acid. As used herein the term "monoclonal antibody" refers to homogeneous populations of immunoglobulins which are capable 15 of specifically binding to Pep714-related peptides. Preferably, antagonists of the invention are derived from monoclonal antibodies specific for Pep714-related peptides. Monoclonal antibodies capable of blocking, or neutralizing, Pep714-related peptides are selected by their ability to inhibit a biological activity of Pep714-related peptides.

The use of antibody fragments is also well known, e.g. Fab fragments: Tijssen, Practice and 20 Theory of Enzyme Immunoassays (Elsevier, Amsterdam, 1985); and Fv fragments: Hochman et al. Biochemistry, Vol. 12, pgs. 1130-1135 (1973), Sharon et al., Biochemistry, Vol. 15, pgs. 1591-1594 (1976) and Ehrlich et al., U.S. Patent 4,355,023; and antibody half molecules: Auditore-Hargreaves, U.S. Patent 4,470,925.

25 Preferably, monoclonal antibodies, Fv fragments, Fab fragments, or other binding compositions derived from monoclonal antibodies of the invention have a high affinity to Pep714-related peptides. The affinity of monoclonal antibodies and related molecules to Pep714-related peptides may be measured by conventional techniques including plasmon resonance, ELISA, and equilibrium dialysis. Affinity measurement by plasmon resonance techniques may be carried out, for example, using a BIACore 2000 instrument (Biacore AB, Uppsala, Sweden) in accordance with 30 the manufacturer's recommended protocol. Preferably, affinity is measured by ELISA, for example, as described in U.S. patent 6,235,883, or like reference. Preferably, the dissociation constant between Pep714-related peptides and monoclonal antibodies of the invention is less than 10^{-5} molar. More preferably, such dissociation constant is less than 10^{-8} molar; still more preferably, such dissociation constant is less than 10^{-9} molar; and most preferably, such dissociation constant is in 35 the range of 10^{-9} to 10^{-11} molar.

In addition, the antibodies of the present invention are useful for detecting Pep714-related peptides. Such detection methods are advantageously applied to diagnosis and prognosis of microbial and viral infection. The antibodies of the invention may be used in most assays involving antigen-antibody reactions. The assays may be homogeneous or heterogeneous. In a homogeneous assay approach, the sample can be a biological sample or fluid such as serum, urine, whole blood, lymphatic fluid, plasma, saliva, cells, tissue, and material secreted by cells or tissues cultured in vitro. The sample can be pretreated if necessary to remove unwanted materials. The immunological reaction usually involves the antigen-specific antibody, labeled antigen, and the sample suspected of containing the antigen. The antigen can be directly labeled with any label group described herein.

In a heterogeneous assay approach, the reagents are usually the sample, the specific antibody, and means for producing a detectable signal. The specimen is generally placed on a support, such as a plate or a slide, and contacted with the antibody in a liquid phase. The support is then separated from the liquid phase and either the support phase or the liquid phase is examined for a detectable signal employing means for producing such signal or signal producing system. The signal is related to the presence of the antigen in the sample. Means for producing a detectable signal includes the use of any label group described herein.

One embodiment of an assay employing an antibody of the present invention involves the use of a surface to which the monoclonal antibody of the invention is attached. The underlying structure of the surface may take different forms, have different compositions and may be a mixture of compositions or laminates or combinations thereof. The surface may assume a variety of shapes and -forms and may have varied dimensions, depending on the manner of use and measurement. Illustrative surfaces may be pads, beads, discs, or strips which may be flat, concave or convex. Thickness is not critical, generally being from about 0.1 to 2 mm thick and of any convenient diameter or other dimensions. The surface typically will be supported on a rod, tube, capillary, fiber, strip, disc, plate, cuvette and will typically be porous and polyfunctional or capable of being polyfunctionalized so as to permit covalent binding of an antibody and permit bonding of other compounds which form a part of a means for producing a detectable signal. A wide variety of organic and inorganic polymers, both natural and synthetic, and combinations thereof, may be employed as the material for the solid surface. Illustrative polymers include polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, latex, paper, glasses, ceramics, metals, metaloids, semiconductor materials, cements, silicates or the like. Also included are substrates that form gels, gelatins, lipopolysaccharides, silicates, agarose and polyacrylamides or polymers which form several aqueous phases such as dextrans, polyalkylene glycols (alkylene of 2 to 3 carbon atoms) or surfactants such as

phospholipids. The binding of the antibody to the surface may be accomplished by well known techniques, commonly available in the literature (See, for example, "Immobilized Enzymes," Ichiro Chibata, Press, New York (1978) and Cuatrecasas, *J. Bio. Chem.*, 245: 3059 (1970)). In carrying out the assay in accordance with this of the invention the sample is mixed with aqueous medium and the medium is contacted with the surface having an antibody bound thereto. Labels may be included in the aqueous medium, either concurrently or added subsequently so as to provide a detectable signal associated with the surface. The means for producing the detectable signal can involve the incorporation of a labeled analyte or it may involve the use of a second monoclonal antibody having a label conjugated thereto. Separation and washing steps will be carried out as needed. The signal detected is related to the presence of Pep714-related peptides in the sample. It is within the scope of the present invention to include a calibration as the measurement surface on the same support. A particular embodiment of an assay in accordance with the present invention, by way of illustration and not limitation, involves the use of a support such as a slide or a well of a petri dish. The technique involves fixing the sample to be analyzed on the support with an appropriate fixing material and incubating the sample on the slide with a monoclonal antibody. After washing with an appropriate buffer such as, for example, phosphate buffered saline, the support is contacted with a labeled specific binding partner for the antibody. After incubation as desired, the slide is washed a second time with an aqueous buffer and the determination is made of the binding of the labeled monoclonal antibody to the antigen. If the label is fluorescent, the slide may be covered with a fluorescent antibody mounting fluid on a cover slip and then examined with a fluorescent microscope to determine the extent of binding. On the other hand, the label can be an enzyme conjugated to the monoclonal antibody and the extent of binding can be determined by examining the slide for the presence of enzyme activity, which may be indicated by the formation of a precipitate, color, etc. A particular example of an assay utilizing the present antibodies is a double determinant ELISA assay. A support such as, e.g., a glass or vinyl plate, is coated with antibody specific for Pep714-related peptides by conventional techniques. The support is contacted with the sample suspected of containing Pep714-related peptides, usually in aqueous medium. After an incubation period from 30 seconds to 12 hours, the support is separated from the medium, washed to remove unbound Pep714-related peptides with, for example, water or an aqueous buffered medium, and contacted with an antibody specific for Pep714-related peptides, again usually in aqueous medium. The antibody is labeled with an enzyme directly or indirectly such as, e.g., horseradish peroxidase or alkaline phosphatase. After incubation, the support is separated from the medium, and washed as above. The enzyme activity of the support or the aqueous medium is determined. This enzyme activity is related to the amount of Pep714-related peptides in the sample.

The invention also includes kits, e.g., diagnostic assay kits, for carrying out the methods

disclosed above. In one embodiment, the kit comprises in packaged combination (a) a monoclonal antibody more specifically defined above and (b) a conjugate of a specific binding partner for the above monoclonal antibody and a label capable of producing a detectable signal. The reagents may also include ancillary agents such as buffering agents and protein stabilizing agents, e.g.,

5 polysaccharides and the like. The kit may further include, where necessary, other members of the signal producing system of which system the label is a member, agents for reducing background interference in a test, control reagents, apparatus for conducting a test, and the like. In another embodiment, the diagnostic kit comprises a conjugate of monoclonal antibody of the invention and a label capable of producing a detectable signal. Ancillary agents as mentioned above may also be

10 present.

Further, an anti-Pep714-related antibody (e.g., monoclonal antibody) can be used to isolate Pep714-related peptide by standard techniques, such as affinity chromatography or immunoprecipitation. For example, an anti-Pep714-related antibody can facilitate the purification of natural Pep714-related peptides from cells and of recombinantly produced Pep714-related peptides

15 expressed in host cells. Moreover, an anti-Pep714-related antibody can be used to isolate Pep714-related peptide to aid in detection of low concentrations of Pep714-related peptide (e.g., in plasma, cellular lysate or cell supernatant) or in order to evaluate the abundance and pattern of expression of the Pep714-related peptide. Anti-Pep714-related antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a

20 given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a label group.

Protein Arrays

Detection, purification, and screening of the polypeptides of the invention may be

25 accomplished using retentate chromatography (preferably, protein arrays or chips), as described by U.S. Patent 6225027 and U.S. Patent Application 20010014461, disclosures of which are herein incorporated by reference in their entireties. Briefly, retentate chromatography describes methods in which polypeptides (and/ or other sample components) are retained on an adsorbent (e.g., array or chip) and subsequently detected. Such methods involve (1) selectively adsorbing polypeptides from

30 a sample to a substrate under a plurality of different adsorbent/eluant combinations ("selectivity conditions") and (2) detecting the retention of adsorbed polypeptides by desorption spectrometry (e.g., by mass spectrometry). In conventional chromatographic methods, polypeptides are eluted off of the adsorbent prior to detection. The coupling of adsorption chromatography with detection by desorption spectrometry provides extraordinary sensitivity, the ability to rapidly analyze retained

35 components with a variety of different selectivity conditions, and parallel processing of components

adsorbed to different sites (i.e., "affinity sites" or "spots") on the array under different elution conditions.

These methods are useful for: combinatorial, biochemical separation and purification of the Pep714-related peptides; study of differential gene expression; detection of differences in protein 5 levels (e.g., for diagnosis); and detection of molecular recognition events, (e.g., for screening and drug discovery). Thus, this invention provides a molecular discovery and diagnostic device that is characterized by the inclusion of both parallel and multiplex polypeptide processing capabilities. Polypeptides of the invention and Pep714-related peptide-binding substances are preferably attached 10 to a label group, and thus directly detected, enabling simultaneous transmission of two or more signals from the same "circuit" (i.e., addressable "chip" location) during a single unit operation.

Detection of Pep714-related peptides by mass spectrometry

In accordance with the present invention, any instrument, method, process, etc. can be utilized to determine the identity and abundance of proteins in a sample. A preferred method of 15 obtaining identity is by mass spectrometry, where protein molecules in a sample are ionized and then the resultant mass and charge of the protein ions are detected and determined.

To use mass spectrometry to analyze proteins, it is preferred that the protein be converted to a gas-ion phase. Various methods of protein ionization are useful, including, e.g., fast ion bombardment (FAB), plasma desorption, laser desorption, thermal desorption, preferably, 20 electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI). Many different mass analyzers are available for peptide and protein analysis, including, but not limited to, Time-of-Flight (TOF), ion trap (ITMS), Fourier transform ion cyclotron (FTMS), quadrupole ion trap, and sector (electric and/or magnetic) spectrometers. See, e.g., U.S. Pat. No. 5,572,025 for an ion-trap MS. Mass analyzers can be used alone, or in combination with other mass analyzers in 25 tandem mass spectrometers. In the latter case, a first mass analyzer can be used to separate the protein ions (precursor ion) from each other and determine the molecular weights of the various protein constituents in the sample. A second mass analyzer can be used to analyze each separated constituents, e.g., by fragmenting the precursor ions into product ions by using, e.g. an inert gas. Any desired combination of mass analyzers can be used, including, e.g., triple quadrupoles, tandem 30 time-of-flights, ion traps, and/or combinations thereof.

Different kinds of detectors can be used to detect the protein ions. For example, destructive detectors can be utilized, such as ion electron multipliers or cryogenic detectors (e.g., U.S. Pat. No. 5,640,010). Additionally, non-destructive detectors can be used, such as ion traps which are used as ion current pick-up devices in quadrupole ion trap mass analyzers or FTMS.

35 For MALDI-TOF, a number of sample preparation methods can be utilized including, dried

droplet (Karas and Hillenkamp, *Anal. Chem.*, 60:2299-2301, 1988), vacuum-drying (Winberger et al., In *Proceedings of the 41st ASMS Conference on Mass Spectrometry and Allied Topics*, San Francisco, May 31-June 4, 1993, pp. 775a-b), crush crystals (Xiang et al., *Rapid Comm. Mass Spectrom.*, 8:199-204, 1994), slow crystal growing (Xiang et al., *Org. Mass Spectrom.*, 28:1424-1429, 1993); active film (Mock et al., *Rapid Comm. Mass Spectrom.*, 6:233-238, 1992; Bai et al., *Anal. Chem.*, 66:3423-3430, 1994), pneumatic spray (Kochling et al., *Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics*; Atlanta, GA, May 21-26, 1995, p1225); electrospray (Hensel et al., *Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics*; Atlanta, GA, May 21 -26, 1995, p947); fast solvent evaporation (Vorm et al., *Anal. Chem.*, 66:3281-3287, 1994); sandwich (Li et al., *J. Am. Chem. Soc.*, 118:11662-11663, 1996); and two-layer methods (Dal et al., *Anal. Chem.*, 71:1087-1091, 1999). See also, e.g., Liang et al., *Rapid Commun. Mass Spectrom.*, 10: 1219-1226, 1996; van Adrichem et al., *Anal. Chem.*, 70:923-930, 1998.

For MALDI analysis, samples are prepared as solid-state co-crystals or thin films by mixing them with an energy absorbing compound or colloid (the matrix) in the liquid phase, and ultimately drying the solution to the solid state upon the surface of an inert probe. In some cases an energy absorbing molecule (EAM) is an integral component of the sample presenting surface. Regardless of EAM application strategy, the probe contents are allowed to dry to the solid state prior to introduction into the laser desorption/ionization time-of-flight mass spectrometer (LDIMS).

Ion detection in TOF mass spectrometry is typically achieved with the use of electro-emissive detectors such as electron multipliers (EMP) or microchannel plates (MCP). Both of these devices function by converting primary incident charged particles into a cascade of secondary, tertiary, quaternary, etc. electrons. The probability of secondary electrons being generated by the impact of a single incident charged particle can be taken to be the ion-to-electron conversion efficiency of this charged particle (or more simply, the conversion efficiency). The total electron yield for cascading events when compared to the total number of incident charged particles is typically described as the detector gain. Because generally the overall response time of MCPs is far superior to that of EMPS, MCPs are the preferred electro-emissive detector for enhancing mass/charge resolving power. However, EMPS function well for detecting ion populations of disbursed kinetic energies, where rapid response time and broad frequency bandwidth are not necessary.

In a preferred aspect, for the analysis of digested proteins, a liquid-chromatography tandem mass spectrometer (LC-TMS) is used. This system provides an additional stage of sample separation via use of a liquid chromatograph followed by tandem mass spectrometry.

The methods described herein of separating and fractionating proteins provide individual

proteins or fractions containing small numbers of distinct proteins. These proteins can be identified by mass spectral determination of the molecular masses of the protein and peptides resulting from the fragmentation thereof. Making use of available information in protein sequence databases, a comparison can be made between proteolytic peptide mass patterns generated *in silico*, and 5 experimentally observed peptide masses. A "hit-list" can be compiled, ranking candidate proteins in the database, based on (among other criteria) the number of matches between the theoretical and experimental proteolytic fragments. Several Web sites are accessible that provide software for protein identification on-line, based on peptide mapping and sequence database search strategies (e.g., <http://www.expasy.ch>). Methods of peptide mapping and sequencing using MS are described 10 in WO 95/252819, U.S. Pat. No. 5,538,897, U.S. Pat. No. 5,869,240, U.S. Pat. No. 5,572,259, and U.S. Pat. No. 5,696,376. See, also, Yates, J. Mass Spec., 33:1 (1998).

15 Data collected from a mass spectrometer typically comprises the intensity and mass to charge ratio for each detected event. Spectral data can be recorded in any suitable form, including, e.g., in graphical, numerical, or electronic formats, either in digital or analog form. Spectra are preferably recorded in a storage medium, including, e.g., magnetic, such as floppy disk, tape, or hard disk; optical, such as CD-ROM or laser-disc; or, ROM-CHIPS.

20 The mass spectrum of a given sample typically provides information on protein intensity, mass to charge ratio, and molecular weight. In preferred embodiments of the invention, the molecular weights of proteins in the sample are used as a matching criterion to query a database. The molecular weights are calculated conventionally, e.g., by subtracting the mass of the ionizing proton for singly-charged protonated molecular ions, by multiplying the measured mass/charge ratio by the 25 number of charges for multiply-charged ions and subtracting the number of ionizing protons.

Various databases are useful in accordance with the present invention. Useful databases 25 include, databases containing genomic sequences, expressed gene sequences, and/or expressed protein sequences. Preferred databases contain nucleotide sequence-derived molecular masses of proteins present in a known organism, organ, tissue, or cell-type. There are a number of algorithms to identify open reading frames (ORF) and convert nucleotide sequences into protein sequence and molecular weight information. Several publicly accessible databases are available, including, the SwissPROT/TrEMBL database (<http://www.expasy.ch>).

30 Typically, a mass spectrometer is equipped with commercial software that identifies peaks above a certain threshold level, calculates mass, charge, and intensity of detected ions. Correlating molecular weight with a given output peak can be accomplished directly from the spectral data, i.e., where the charge on an ion is one and the molecular weight is therefore equal to the numerator value 35 minus the mass of the ionizing proton. However, protein ions can be complexed with various counter-ions and adducts, such as N, C, and K'. In such a case, it would be expected that a given

protein ion would exhibit multiple peaks, such as a triplet, representing different ionic states (or species) of the same protein. Thus, it may be necessary to analyze and process spectral data to determine families of peaks arising from the same protein. This analysis can be carried out conventionally, e.g., as described by Mann et al., anal. Chem., 61:1702-1708 (1989).

5 In matching a molecular mass calculated from a mass spectrometer to a molecular mass predicted from a database, such as a genomic or expressed gene database, post-translation processing may have to be considered. There are various processing events which modify protein structure, including, proteolytic processing, removal of N-terminal methionine, acetylation, methylation, glycosylation, phosphorylation, etc.

10 A database can be queried for a range of proteins matching the molecular mass of the unknown. The range window can be determined by the accuracy of the instrument, the method by which the sample was prepared, etc. Based on the number of hits (where a hit is match) in the spectrum, the unknown protein or peptide is identified or classified.

15 Methods of identifying one or more Pep714-related peptide by mass spectrometry are useful for detection of one or more Pep714-related peptide present in human plasma. Exemplary techniques are described in U.S. Patent Applications 02/0060290, 02/0137106, 02/0138208, 02/0142343, 02/0155509, disclosures of which are incorporated by reference in their entireties.

Diagnostic and Prognostic Uses

20 The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics as further described herein.

25 The invention provides diagnostic and prognostic assays for detecting Pep714-related peptide nucleic acids and proteins, as further described. Also provided are diagnostic and prognostic assays for detecting interactions between Pep714-related peptides and target molecules, particularly natural agonists and antagonists.

30 The present invention provides methods for identifying polypeptides that are differentially expressed between two or more samples. "Differential expression" refers to differences in the quantity or quality of a polypeptide between samples. Such differences could result at any stage of protein expression from transcription through post-translational modification. For example, using protein array methods, two samples are bound to affinity spots on different sets of adsorbents (e.g., chips) and recognition maps are compared to identify polypeptides that are differentially retained by the two sets of adsorbents. Differential retention includes quantitative retention as well as qualitative differences in the polypeptide. For example, differences in post-translational modification of a 35 protein can result in differences in recognition maps detectable as differences in binding

characteristics (e.g., glycosylated proteins bind differently to lectin adsorbents) or differences in mass (e.g., post-translational cleavage products). In certain embodiments, an adsorbent can have an array of affinity spots selected for a combination of markers diagnostic for a disease or syndrome.

Differences in polypeptide levels between samples (e.g., differentially expressed Pep714-

5 related peptides in plasma samples) can be identified by exposing the samples to a variety of conditions for analysis by desorption spectrometry (e.g., mass spectrometry). Unknown proteins can be identified by detecting physicochemical characteristics (e.g., molecular mass), and this information can be used to search databases for proteins having similar profiles.

Preferred methods of detecting a Pep714-related peptide utilize mass spectrometry

10 techniques. Such methods provide information about the size and character of the particular Pep714-related peptide isoform that is present in a sample, e.g., a biological sample submitted for diagnosis or prognosis. Mass spectrometry techniques are detailed in the section titled "Detection of Pep714-related peptides by mass spectrometry". The invention provides a method of detecting a Pep714-related peptide in a biological sample comprising the steps of: fractionating a biological 15 sample (e.g., serum, lymph, cerebrospinal fluid; cell lysate of a particular tissue) by at least one chromatographic step; subjecting a fraction to mass spectrometry; comparing the characteristics of peptide species observed in mass spectrometry with known characteristics of Pep714-related peptides.

The isolated nucleic acid molecules of the invention can be used, for example, to detect

20 Pep714-related mRNA (e.g., in a biological sample) or a genetic alteration in a Pep714-encoding gene, and to modulate a Pep714-related peptide activity, as described further below. The Pep714-related peptide can be used to treat disorders characterized by insufficient production of a Pep714-related peptide or by excessive production of a Pep714-related peptide target molecule. In addition, the Pep714-related peptides can be used to screen for naturally occurring target molecules, to screen 25 for drugs or compounds which modulate, preferably activate Pep714-related peptide activity, as well as to treat disorders characterized by insufficient production of Pep714-related peptide or production of Pep714-related peptide forms which have decreased or aberrant activity compared to wild type. Moreover, the anti- Pep714-related peptide antibodies of the invention can be used to detect and isolate Pep714-related peptide, regulate the bioavailability of Pep714-related peptide, and modulate 30 Pep714-related peptide activity.

Accordingly one embodiment of the present invention involves a method of use (e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a molecule of the present invention (e.g., a Pep714-related peptide, Pep714-related nucleic acid, or Pep714-related peptide inhibitor or activator) is used, for example, to diagnose, prognose and/or 35 treat a disorder in which any of the aforementioned Pep714-related peptide activities is indicated. In

another embodiment, the present invention involves a method of use (e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a molecule of the present invention is used, for example, for the diagnosis, prognosis, and/or treatment of subjects, preferably a human subject, in which any of the aforementioned activities is pathologically perturbed. In a preferred embodiment, the methods of use involve administering to a subject, preferably a human subject, a molecule of the present invention for the diagnosis, prognosis, and/or therapeutic treatment. In another embodiment, the methods of use involve administering to a human subject a molecule of the present invention.

For example, the invention encompasses a method of determining whether a Pep714-related peptide is expressed within a biological sample comprising: a) contacting said biological sample with: i) a polynucleotide that hybridizes under stringent conditions to a Pep714-related nucleic acid; or ii) a detectable polypeptide (e.g. antibody) that selectively binds to a Pep714-related peptide; and b) detecting the presence or absence of hybridization between said polynucleotide and an RNA species within said sample, or the presence or absence of binding of said detectable polypeptide to a polypeptide within said sample. Detection of said hybridization or of said binding indicates that said Pep714-related peptide is expressed within said sample. Preferably, the polynucleotide is a primer, and wherein said hybridization is detected by detecting the presence of an amplification product comprising said primer sequence, or the detectable polypeptide is an antibody.

In certain embodiments, detection involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202, the disclosures of which are incorporated herein by reference in their entireties), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegren et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *PNAS* 91:360-364, the disclosures of which are incorporated herein by reference in their entireties), the latter of which can be particularly useful for detecting point mutations in the Pep714-related peptide-encoding-gene (see Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682, the disclosure of which is incorporated herein by reference in its entirety).

Also envisioned is a method of determining whether a mammal, preferably human, has an elevated or reduced level of expression of a Pep714-related peptide, comprising: a) providing a biological sample from said mammal; and b) comparing the amount of a Pep714-related peptide or of a Pep714-related RNA species within said biological sample with a level detected in or expected from a control sample. An increased amount of said Pep714-related peptide or said RNA species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal has an elevated level of Pep714-related peptide expression, and a decreased amount of said Pep714-related peptide or said RNA species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal

has a reduced level of expression of a Pep714-related peptide.

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to 5 diagnostic assays for determining Pep714-related peptide and/or nucleic acid expression as well as Pep714-related peptide activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant Pep714-related peptide expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is 10 at risk of developing a disorder associated with a Pep714-related peptide, nucleic acid expression or activity. For example, mutations in a Pep714-related peptide -encoding gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with Pep714-related peptide expression or activity.

15 The term "biological sample" is intended to include tissues, cells and biological fluids isolated from an individual, as well as tissues, cells and fluids present within an individual. That is, the detection methods of the invention can be used to detect a Pep714-related peptide mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. Preferred biological samples are biological fluids such as lymph, cerebrospinal fluid, blood, and especially blood serum. 20 For example, *in vitro* techniques for detection of a Pep714-related peptide mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a Pep714-related peptide include mass spectrometry, enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of a Pep714-related peptide -encoding genomic DNA include Southern hybridizations. Furthermore, *in vivo* 25 techniques for detection of a Pep714-related peptide include introducing into an individual a labeled anti- Pep714-related peptide antibody.

In preferred embodiments, the subject methods can be characterized by generally comprising detecting, in a tissue sample of the individual (e.g. a human patient), the presence or absence of a genetic lesion characterized by at least one of (i) a mutation of a gene encoding one of the subject 30 Pep714-related peptide or (ii) the mis-expression of a Pep714 gene. To illustrate, such genetic lesions can be detected by ascertaining the existence of at least one of (i) a deletion of one or more nucleotides from the Pep714 gene, (ii) an addition of one or more nucleotides to the gene, (iii) a substitution of one or more nucleotides of the gene, (iv) a gross chromosomal rearrangement or amplification of the gene, (v) a gross alteration in the level of a messenger RNA transcript of the 35 gene, (vi) aberrant modification of the gene, such as of the methylation pattern of the genomic DNA,

(vii) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene, and
(viii) reduced level of expression, indicating lesion in regulatory element or reduced stability of a Pep714-related transcript.

In yet another exemplary embodiment, aberrant methylation patterns of a Pep714-related peptide nucleic acid can be detected by digesting genomic DNA from a patient sample with one or more restriction endonucleases that are sensitive to methylation and for which recognition sites exist in the Pep714 gene (including in the flanking and intronic sequences). See, for example, Buiting et al. (1994) *Human Mol Genet* 3:893-895. Digested DNA is separated by gel electrophoresis, and hybridized with probes derived from, for example, genomic or cDNA sequences. The methylation status of the Pep714 gene can be determined by comparison of the restriction pattern generated from the sample DNA with that for a standard of known methylation.

In yet another embodiment, a diagnostic assay is provided which detects the ability of a Pep714-related peptide to bind to a cell surface or extracellular protein. For instance, it will be desirable to detect Pep714-related peptide mutants which, while expressed at appreciable levels in the cell, are defective at binding a Pep714-related peptide target protein (having either diminished or enhanced binding affinity for the target). Such mutants may arise, for example, from mutations, e.g., point mutants, which may be impractical to detect by the diagnostic DNA sequencing techniques or by the immunoassays described above. The present invention accordingly further contemplates diagnostic screening assays which generally comprise cloning one or more Pep714 gene from the sample tissue, and expressing the cloned genes under conditions which permit detection of an interaction between that recombinant gene product and a target protein. As will be apparent from the description of the various assays set forth herein under the Section entitled "Drug screening assays", a wide variety of techniques can be used to determine the ability of a Pep714-related peptide to bind to other components. These techniques can be used to detect mutations in a Pep714 gene which give rise to mutant proteins with a higher or lower binding affinity for a Pep714 target protein relative to the wild-type Pep714-related peptide. Conversely, by switching which of the Pep714 target protein and Pep714-related peptide is the "bait" and which is derived from the patient sample, the subject assay can also be used to detect target protein mutants which have a higher or lower binding affinity for a Pep714-related peptide relative to a wild type form of that target protein.

In an exemplary embodiment, a target protein can be provided as an immobilized protein (a "target"), such as by use of GST fusion proteins and glutathione treated microtitre plates as described herein.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a Pep714-related peptide, mRNA, or genomic DNA, such that the presence of a Pep714-related

peptide, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of a Pep714-related peptide, mRNA or genomic DNA in the control sample with the presence of a Pep714-related peptide, mRNA or genomic DNA in the test sample. The invention also encompasses kits for detecting the presence of a Pep714-related peptide, mRNA or genomic DNA in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting a Pep714-related peptide, mRNA or genomic DNA in a biological sample; means for determining the amount of a Pep714-related peptide in the sample; and means for comparing the amount of Pep714-related peptide in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect Pep714-related peptide or nucleic acid.

Non-therapeutic uses of Pep714-related peptides

Pep714-related peptides are effective, alone or mixed with other adjuvants, in reducing microbial and viral populations on solid materials and fluids such as: air and liquid filtration equipment, filtering agents, belt sprays, liquid transport lines, textiles, disposable paper or textile products, boot and hand-washes, storage and preparation containers, aseptic packaging, foods, food and medical surfaces, food and medical washes, biological fluids, and food and medical equipment. Preparations for foodstuffs and foodstuff containers may be prepared according to the methods of U.S. Patent 5573800, disclosure of which is incorporated herein in its entirety. The proteins of the invention may be applied as part of a cleansing or sanitizing solution (e.g., WO 00/57730 or via the prepackaged treatment disclosed in U.S. Patent 4998984, disclosures of which are incorporated by reference in their entireties) or as a coating treatment for the solid material. Forms include powder, liquid, pellet or solid. The invention also resides in Pep714-related peptide powder antimicrobial or antiviral compositions suitable for incorporation (casting, absorbing, adsorbing, spray-drying, etc.,) into solid, elastomeric, or fibrous substrates for residual antimicrobial or antiviral effects. The invention also resides in a method of washing and reducing microbial or viral concentrations by treating materials or solutions with a dilute aqueous solution including about 0.1 to 400 grams per liter of water of the dissolved powder, solid, gel, aerosol, or liquid compositions defined above.

30 Drug screening assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators (e.g., small molecules and peptides, antibodies, peptidomimetics or other drugs) which bind to Pep714-related peptides, have an inhibitory or activating effect on, for example, Pep714-related peptides expression or preferably Pep714-related biological activity, or have an inhibitory or activating effect on, for example, the activity of a Pep714-related target

molecule. In some embodiments small molecules can be generated using combinatorial chemistry or can be obtained from a natural products library. Assays may be cell based or non-cell based assays. Drug screening assays may be binding assays or more preferentially functional assays, as further described.

5 Agents that are found to increase Pep714-related peptide activity may be used, for example, as antimicrobial or antiviral agents alone or in combination with other appropriate agents or treatments. Agents found to inhibit Pep714-related peptide activity may be used, for example, to modulate antimicrobial or antiviral treatment regimens or to promote survival of beneficial microbial agents.

10 Protein array methods are useful for screening and drug discovery. For example, one member of a receptor/ ligand pair is docked to an adsorbent, and its ability to bind the binding partner is determined in the presence of the test substance. Because of the rapidity with which adsorption can be tested, combinatorial libraries of test substances can be easily screened for their ability to modulate the interaction. In preferred screening methods, Pep714-related peptides are 15 docked to the adsorbent. Binding partners are preferably labeled, thus enabling detection of the interaction.

20 Alternatively, in certain embodiments, a test substance is docked to the adsorbent. The polypeptides of the invention are exposed to the test substance and screened for binding. Preferred test substances include substances correlated with a disease or disorder, such as a protein, lipid, or endocrine factor differentially present in disease (preferably, a microbial or viral related disease).

25 In other embodiments, an assay is a cell-based assay in which a cell which expresses a Pep714-related peptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to inhibit, activate, or increase Pep714-related activity determined. Determining the ability of the test compound to inhibit, activate, or increase Pep714-related activity can be accomplished by monitoring the bioactivity of the Pep714-related peptide or biologically 30 active portion thereof. The cell, for example, can be of mammalian origin, insect origin, bacterial origin or a yeast cell.

35 In one embodiment, the invention provides assays for screening candidate or test compounds which are target molecules of a Pep714-related peptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a Pep714-related peptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using

affinity chromatography selection. The biological library approach is used with peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K. S. (1997) *Anticancer Drug Des.* 12:145, the disclosure of which is incorporated herein by reference in its entirety). Preferred libraries for screening Pep714-related peptides of the invention include libraries of viral and microbially expressed proteins.

5 Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al. (1994) *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop et al. (1994) *J. Med. Chem.* 37:1233, the disclosures of which are incorporated herein by reference in their entireties.

10 Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner U.S. Pat. No. '409), plasmids (Cull 15 et al. (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devin (1990) *Science* 249:404-406); (Cwirla et al. (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*), the disclosures of which are incorporated herein by reference in their entireties.

20 Determining the ability of the test compound to inhibit or increase Pep714-related activity can also be accomplished, for example, by coupling the Pep714-related peptide or biologically active portion thereof with a label group such that binding of the Pep714-related peptide or biologically active portion thereof to its cognate target molecule can be determined by detecting the labeled Pep714-related peptide or biologically active portion thereof in a complex. For example, the extent 25 of complex formation may be measured by immunoprecipitating the complex or by performing gel electrophoresis.

It is also within the scope of this invention to determine the ability of a compound (e.g., Pep714-related peptide or biologically active portion thereof) to interact with its cognate target molecule without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with its cognate target molecule without the labeling of 30 either the compound or the target molecule. McConnell, H. M. et al. (1992) *Science* 257:1906-1912, the disclosure of which is incorporated by reference in its entirety. A microphysiometer such as a cytosensor is an analytical instrument that measures the rate at which a cell acidifies its environment using a Light-Addressable Potentiometric Sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between compound and receptor.

35 In a preferred embodiment, the assay comprises: contacting a cell which expresses a

Pep714-related peptide or biologically active portion thereof with a target molecule to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to inhibit or increase the activity of the Pep714-related peptide or biologically active portion thereof. Determining the ability of the test compound to inhibit or increase the activity of the

5 Pep714-related peptide or biologically active portion thereof comprises: determining the ability of the test compound to inhibit or increase a biological activity of the Pep714-related peptides expressing cell (e.g., formation of intermolecular amino acid side chain interactions, formation of a cyclic structure, or interaction with a Pep714-related target molecule, as discussed above).

In another preferred embodiment, the assay comprises contacting a cell which is responsive to a Pep714-related peptide or biologically active portion thereof with a Pep714-related peptide or biologically active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to modulate the activity of the Pep714-related peptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the Pep714-related peptide or biologically active portion thereof comprises 10 determining the ability of the test compound to modulate a biological activity of the Pep714-related responsive cell.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a Pep714-related target molecule (i.e. a molecule with which Pep714-related peptides interact) with a test compound and determining the ability of the test compound to modulate (e.g. 15 stimulate or inhibit) the activity of the Pep714-related target molecule. Determining the ability of the test compound to modulate the activity of a Pep714-related target molecule can be accomplished, for example, by determining assessing the activity of a target molecule, or by assessing the ability of the Pep714-related peptide to bind to or interact with the Pep714-related target molecule.

Determining the ability of the Pep714-related peptide to bind to or interact with a Pep714-related target molecule, for example, can be accomplished by one of the methods described above for directly or indirectly determining binding. In a preferred embodiment, the assay includes 20 contacting the Pep714-related peptide or biologically active portion thereof with a known compound which binds said Pep714-related peptide (e.g., a Pep714-related antibody or target molecule) to form an assay mixture, contacting the Pep714-related peptide with a test compound before or after said known compound, and determining the ability of the test compound to interact with the Pep714-related peptide. Determining the ability of the test compound to interact with a Pep714-related peptide comprises determining the ability of the test compound to preferentially bind to Pep714-related peptides or biologically active portion thereof as compared to the known compound. 25 Determining the ability of the Pep714-related peptide to bind to a Pep714-related target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis

(BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo et al. (1995) *Curr. Opin. Struct. Biol.* 5:699-705, the disclosures of which are incorporated herein by reference in their entireties. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIACore). Changes in the optical phenomenon of 5 surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In another embodiment, the assay is a cell-free assay in which a Pep714-related peptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the Pep714-related peptide or 10 biologically active portion thereof is determined. In a preferred embodiment, determining the ability of the Pep714-related peptide to modulate or interact with a Pep714-related target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by contacting the target molecule with the Pep714-related peptide or a fragment thereof and measuring induction of a cellular second messenger of the target (e.g., 15 STAT3, Akt, intracellular Ca²⁺, diacylglycerol, IP₃, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a target-regulated cellular response, for example, signal transduction or protein:protein interactions.

20 The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins (e.g. Pep714-related peptides or biologically active portions thereof or molecules to which Pep714-related peptides targets bind). In the case of cell-free assays in which a membrane-bound form an isolated protein is used it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the isolated protein is maintained in 25 solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton TM X-100, Triton TM X-114, Thesit TM, Isotridecyloxy(ethylene glycol ether)n,3-[(3-cholamidopropyl)dimethylammonio]- 1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-30 dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either a Pep714-related peptide or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a Pep714-related peptide, or interaction of a 35 Pep714-related peptide with a target molecule in the presence and absence of a candidate compound,

can be accomplished in any vessel suitable for containing the reactants and by any immobilization protocol described herein. Alternatively, the complexes can be dissociated from the matrix, and the level of Pep714-related peptides binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a Pep714-related peptide or a Pep714-related target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated Pep714-related peptide or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with Pep714-related peptide or target molecules but which do not interfere with binding of the Pep714-related peptide to its target molecule can be derivatized to the wells of the plate, and unbound target or Pep714-related peptide trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the Pep714-related peptide or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the Pep714-related peptide or target molecule.

In another embodiment, modulators of Pep714-related peptides expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of Pep714-related peptides mRNA or protein in the cell is determined. The level of expression of Pep714-related peptides mRNA or protein in the presence of the candidate compound is compared to the level of expression of Pep714-related peptides mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of Pep714-related peptides expression based on this comparison. For example, when expression of Pep714-related peptides mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of Pep714-related peptides mRNA or protein expression. Alternatively, when expression of Pep714-related peptides mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of Pep714-related peptides mRNA or protein expression. The level of Pep714-related peptides mRNA or protein expression in the cells can be determined by methods described herein for detecting Pep714-related peptides mRNA or protein.

In yet another aspect of the invention, the Pep714-related peptides can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent

WO94/10300, the disclosures of which are incorporated herein by reference in their entireties), to identify other proteins, which bind to or interact with Pep714-related peptides ("Pep714-related peptides-binding proteins" or "Pep714-related peptides-bp") and are involved in Pep714-related activity. Such Pep714-related peptides-binding proteins are also likely to be involved in the 5 propagation of signals by the Pep714-related peptides or Pep714-related peptides targets as, for example, downstream elements of a Pep714-related peptides-mediated signaling pathway. Alternatively, such Pep714-related peptides-binding proteins are likely to be Pep714-related inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which 10 consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a Pep714-related peptide or a fragment thereof is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an 15 unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a Pep714-related peptides-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing 20 the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the Pep714-related peptide.

This invention further pertains to novel agents identified by the above-described screening assays and to processes for producing such agents by use of these assays. Accordingly, in one embodiment, the present invention includes a compound or agent obtainable by a method comprising 25 the steps of any one of the aforesaid screening assays (e.g., cell-based assays or cell-free assays).

Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a Pep714-related peptides modulating agent, or a Pep714-related peptides-binding 30 partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein. Preferably, such agents activate or enhance Pep714-related biological activity.

35 The present invention also pertains to uses of novel agents identified by the above-described

screening assays for diagnoses, prognoses, prevention, and treatments as described herein.

Accordingly, it is within the scope of the present invention to use such agents in the design, formulation, synthesis, manufacture, and/or production of a drug or pharmaceutical composition for use in diagnosis, prognosis, or treatment, as described herein. For example, in one embodiment, the

5 present invention includes a method of synthesizing or producing a drug or pharmaceutical composition by reference to the structure and/or properties of a compound obtainable by one of the above-described screening assays. For example, a drug or pharmaceutical composition can be synthesized based on the structure and/or properties of a compound obtained by a method in which a cell which expresses a Pep714-related target molecule is contacted with a test compound and the
10 ability of the test compound to bind to, or modulate the activity of, the Pep714-related target molecule is determined. In another exemplary embodiment, the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition based on the structure and/or properties of a compound obtainable by a method in which a Pep714-related peptide or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind
15 to, or modulate (e.g., stimulate or inhibit) the activity of, the Pep714-related peptide or biologically active portion thereof is determined.

Pharmaceutical Compositions

When polypeptides of the present invention are expressed in soluble form, for example as a secreted product of transformed yeast or mammalian cells, they can be purified according to standard procedures of the art, including steps of ammonium sulfate precipitation, ion exchange chromatography, gel filtration, electrophoresis, affinity chromatography, according to, e.g., "Enzyme Purification and Related Techniques," Methods in Enzymology, 22:233-577 (1977), and Scopes, R., Protein Purification: Principles and Practice (Springer-Verlag, New York, 1982) provide guidance in such purifications. Likewise, when polypeptides of the invention are expressed in insoluble form, for example as aggregates or inclusion bodies, they can be purified by appropriate techniques, including separating the inclusion bodies from disrupted host cells by centrifugation, solubilizing the inclusion bodies with chaotropic and reducing agents, diluting the solubilized mixture, and lowering the concentration of chaotropic agent and reducing agent so that the polypeptide takes on a
25 biologically active conformation. The latter procedures are disclosed in the following references, which are incorporated by reference: Winkler et al, Biochemistry, 25: 4041-4045 (1986); Winkler et al, Biotechnology, 3: 992-998 (1985); Koths et al, U.S. patent 4,569,790; and European patent
30 applications 86306917.5 and 86306353.3.

Compounds capable of modulating and preferably increasing a Pep714-related biological activity, preferably small molecules but also including peptides, Pep714-related nucleic acid
35

molecules, Pep714-related peptides, and anti-Pep714-related antibodies of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, 5 coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

10 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline 15 solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The 20 parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

25 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol 30 (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the 35 like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols

such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Where the active compound is a protein, e.g., a Pep714-related peptide, sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and other required ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Most preferably, active compound is delivered to a subject by intravenous injection.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, the disclosure of which is incorporated herein by reference

in its entirety.

In a further embodiment, the active compound (e.g., a Pep714-related peptide) may be coated on a microchip drug delivery device. Such devices are useful for controlled delivery of proteinaceous compositions into the bloodstream, cerebrospinal fluid, lymph, or tissue of an 5 individual without subjecting such compositions to digestion or subjecting the individual to injection. Methods of using microchip drug delivery devices are described in US Patents 6,123,861 and 5,797,898 and US Patent application 20020119176A1, disclosures of which are hereby incorporated in their entireties.

It is especially advantageous to formulate oral or preferably parenteral compositions in 10 dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique 15 characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard 20 pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to 25 design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating 30 a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

The pharmaceutical compositions can be included in a container, pack, or dispenser together 35 with instructions for administration.

Therapeutic Uses of Pep714-Related peptides

The Pep714-related peptides of the invention can be used in the treatment or prevention of microbial or viral infections, particularly for inhibiting the growth of microbes and viral infection of host cells. Unlike defensins which accumulate in the granules of phagocytes are toxic to the host when released, the peptides of the invention are normally secreted and are thought not to be toxic to a subject to which they are administered. Thus, in one aspect the invention relates to pharmaceutical compositions containing Pep714-related peptides as active ingredients, preferably containing a pharmaceutically acceptable carrier or diluent. The carrier or diluent is preferably adapted for oral, intravenous, intramuscular or subcutaneous administration. Pep714-related peptides can also be prepared as solutions for inhalation. Pharmaceutical compositions may comprise, consist or consist essentially any of the Pep714-related peptides described herein. Optionally, a Pep714-related peptide can be administered as a cathelicidin propeptide or prepropeptide.

Pep714-related peptides can be used for inhibiting microbial growth in vitro or in vivo.

Preferably the Pep714-related peptides are used for inhibiting microbial growth in animals, preferably in humans. The applications for pep714-related peptides are numerous, including preferably any condition where it is useful to have antimicrobial activity against bacteria without being cytotoxic. In one example, Pep714-related peptides are used in the treatment of chemotherapy- and radiotherapy-induced oral mucositis. Chemotherapy and radiotherapy for the treatment of cancer typically damages the lining of the mouth often resulting in infection. The resulting ulceration of the mouth and tongue is painful and in many cases prevents the patient from eating, drinking or sleeping. Patients often require morphine to relieve the pain. Oral mucositis is often identified by cancer patients as the single worst side effect of chemotherapy and radiation therapy. The oral lesions can also allow bacteria to enter the blood stream causing life-threatening infections.

Preferably Pep714-related peptides can be administered to a subject suffering from oral mucositis or a patient undergoing chemotherapy or radiotherapy in an oral formulation.

In another example, Pep714-related peptides are used in the treatment of ventilator-associated pneumonia. Ventilator-associated pneumonia (VAP) is a hospital-acquired bacterial pneumonia that can develop in patients receiving mechanical ventilation. Aspiration of organisms from the aerodigestive tract while the patient is on mechanical ventilation leads to the onset of VAP. The peptides of the invention may thus be useful for delivery in solution for inhalation for reducing the burden of bacterial colonization of the aerodigestive tract. In another treatment method, Pep714-related peptides are used in the treatment chronic respiratory infections. For example, peptides of the invention can be delivered as an inhalable solution for reducing the amount of bacteria in the lungs of patients with cystic fibrosis.

Preferably, the Pep714-related peptides are used for inhibiting infection of cells targeted by a virus, in particular, HIV. The peptides of the invention may thus be used prophylactically for individuals at a high risk of viral infection (for example, in the case of HIV, human intravenous drug users) or to prevent progression of the infection in already affected individuals. The peptides may 5 be used alone or in combination with other agents as part of a treatment regimen. Such protein-based strategies are reviewed, for example, by E. DeClerq, *Med Res Rev.* (2000) 20:323-49, disclosure of which is hereby incorporated by reference in its entirety.

Having generally described this invention, a further understanding can be obtained by 10 reference to certain specific examples which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

EXAMPLES

15 *Example 1: Purification and Characterisation of a Pep714-related peptide*

Human plasma was fractionated by a series of multiple chromatography columns. The fractions were analysed by mass spectrometry. Three distinct tryptic fragments were found to belong to the protein sequence of Figure 1 by tandem and MALDI mass spectrometry: CMGTVTLNQAR, GSFDISCDK and FALLGDFFRK.

20 *Example 2: Structural analysis of the Pep714-related peptides of the invention*

The Pep714-related peptides of the invention (SEQ ID NO: 6) were found to have close homology with a number of peptides whose structure and anti-viral or anti-microbial activities have been reported earlier (Frechet D, et al., *Biochemistry*, 1994 Jan 11;33(1):42-50; Constantine KL, et 25 al., *J Biomol NMR* 1995 Apr;5(3):271-86; Katahira R, et al., *Bioorg Med Chem.* 1996 Jan;4(1):121-9). For example, the RBP peptide, whose alignment with a Pep714-related peptide of the invention is shown in Figure 2, has been shown to undergo cyclisation between the Cys in position 1 and Asp at position 15 (Frechet et al, *supra*). The RBP peptide possesses 4 Cys residues, known to form two internal disulfide bridges, whereas the Pep714-related peptides of the invention have only 2 Cys 30 residues. However, both of these configurations are known to be prone to a cyclic tertiary fold and have the characteristics of bactericidal activity (US Patent 5,916,872). The structural algorithms Rosetta 1.2 (Bonneau, R. and Baker, D. *Ann Rev Biophys Biomol Struct.* 30:173-189 (2001)) and ICM v2.8.215 with a biased probability Monte Carlo method (Abagyan, R.A. and Totrov, M.M. *J Mol Biol* 235:983-1002 (1994)) were used to confirm the homology predictions based on the 35 primary sequence. Figure 3 illustrates a proposed fold for the FALL-39 propeptide (defined in the Swiss Prot entry P49913), *i.e.* the chain remaining after removal of the signal sequence (30 amino

acids at the N-terminus) and after cleavage of the anti-bacterial protein FALL-39 (39 amino acids at the C-terminus). This structure was arrived at by *ab initio* folding using the Rosetta software (above). The Pep714 peptide of the invention (residues C108 to R131), while attached to the propeptide, can be seen to form a double-stranded beta sheet structure, closed at one end by a loop, 5 and at the other end by the disulfide bond C108-C125.

Figure 4 illustrates a predicted structure of Pep714, calculated with the ICM software (above), based on stabilization of the cyclic structure by an amide bond between the aspartate residue at position 21 (in SEQ ID NO:6) and the cysteine residue at position 1 (in SEQ ID NO:6). As is obvious from visual comparison of the folding patterns of the propeptide (Figure 3) and the 10 processed Pep714 peptide (Figure 4), the Pep714 peptide possesses different structural properties once it has been released from the propeptide and thus presents unique sites for interaction (e.g., protein-protein interactions) which were sterically hindered before the structural rearrangements.

15 *Example 3: Chemical Synthesis of a Pep714-related peptide*

In this example, a Pep714-related peptide of the invention is synthesized. Peptide fragment intermediates are first synthesized and then assembled into the desired polypeptide.

A Pep714-related peptide can initially be prepared in, e.g. 5 fragments, selected to have a Cys residue at the N-terminus of the fragment to be coupled. Fragment 1 is initially coupled to fragment 20 2 to give a first product, then after preparative HPLC purification, the first product is coupled to fragment 3 to give a second product. After preparative HPLC purification, the second product is coupled to fragment 4 to give a third product. Finally, after preparative HPLC purification, the third product is coupled to fragment 5 to give the desired polypeptide, which is purified and refolded.

25 *Thioester formation.*

Fragments 2, 3, 4, and 5 are synthesized on a thioester generating resin, as described above. For this purpose the following resin is prepared: S-acetylthioglycolic acid pentafluorophenylester is coupled to a Leu-PAM resin under conditions essentially as described by Hackeng et al (1999). In the first case, the resulting resin is used as a starting resin for peptide chain elongation on a 0.2 mmol 30 scale after removal of the acetyl protecting group with a 30 min treatment with 10% mercaptoethanol, 10% piperidine in DMF. The N^α of the N-terminal Cys residues of fragments 2 through 5 are protected by coupling a Boc-thioproline (Boc-SPr, i.e. Boc-L-thioproline) to the terminus of the respective chains instead of a Cys having conventional N^α or S^β protection, e.g. Brik et al, J. Org. Chem., 65: 3829-3835 (2000).

Peptide synthesis

Solid-phase synthesis is performed on a custom-modified 433A peptide synthesizer from Applied Biosystems, using *in situ* neutralization/2-(1H-benzotriazol-1-yl)-1,1,1,3,3-tetramethyluronium hexafluoro-phosphate (HBTU) activation protocols for stepwise Boc chemistry 5 chain elongation, as described by Schnolzer et al, Int. J. Peptide Protein Res., 40: 180-193 (1992).

Each synthetic cycle consists of N^{α} -Boc -removal by a 1 to 2 min treatment with neat TFA, a 1-min DMF flow wash, a 10-min coupling time with 2.0 mmol of preactivated Boc-amino acid in the presence of excess DIEA and a second DMF flow wash. N^{α} -Boc-amino acids (2 mmol) are preactivated for 3min with 1.8mmol HBTU (0.5M in DMF) in the presence of excess DIEA 10 (6mmol). After coupling of Gln residues, a dichloromethane flow wash is used before and after deprotection using TFA, to prevent possible high temperature (TFA/DMF)-catalyzed pyrrolidone carboxylic acid formation. Side-chain protected amino acids are Boc-Arg(p-toluenesulfonyl)-OH, Boc-Asn(xanthyl)-OH, Boc-Asp(O-cyclohexyl)-OH, Boc-Cys(4-methylbenzyl)-OH, Boc-Glu(O-cyclohexyl)-OH, Boc-His(dinitrophenylbenzyl)-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Ser(benzyl)-OH, 15 Boc-Thr(benzyl)-OH, Boc-Trp(formyl)-OH and Boc-Tyr(2-Br-Z)-OH (Orpagen Pharma, Heidelberg, Germany). Other amino acids are used without side chain protection. C-terminal Fragment 1 is synthesized on Boc-Leu-O-CH₂-Pam resin (0.71mmol/g of loaded resin), while for Fragments 2 through 5 machine-assisted synthesis is started on the Boc-Xaa-S-CH₂-CO-Leu-Pam 20 resin. This resin is obtained by the coupling of S-acetylthioglycolic acid pentafluorophenylester to a Leu-PAM resin under standard conditions. The resulting resin is used as a starting resin for peptide chain elongation on a 0.2 mmol scale after removal of the acetyl protecting group with a 30min treatment with 10% mercaptoethanol, 10% piperidine in DMF.

After chain assembly is completed, the peptide fragments are deprotected and cleaved from the resin by treatment with anhydrous hydrogen fluoride for 1hr at 0°C with 5% p-cresol as a 25 scavenger. In all cases except Fragment 1, the imidazole side chain 2,4-dinitrophenyl (DNP) protecting groups remain on His residues because the DNP-removal procedure is incompatible with C-terminal thioester groups. However DNP is gradually removed by thiols during the ligation reaction, yielding unprotected His. After cleavage, peptide fragments are precipitated with ice-cold diethylether, dissolved in aqueous acetonitrile and lyophilized. The peptide fragments are purified by 30 RP-HPLC with a C18 column from Waters by using linear gradients of buffer B (acetonitile/0.1% trifluoroacetic acid) in buffer A (H₂O/0.1% trifluoroacetic acid) and UV detection at 214nm. Samples are analyzed by electrospray mass spectrometry (ESMS) using an Esquire instrument (Brücker, Bremen , Germany), or like instrument.

Native chemical ligations

As described more fully below, the ligation of unprotected fragments is performed as follows: the dry peptides are dissolved in equimolar amounts in 6M guanidine hydrochloride (GuHCl), 0.2M phosphate, pH 7.5 in order to get a final peptide concentration of 1-8 mM at a pH around 7, and 1% benzylmercaptan, 1% thiophenol is added. Usually, the reaction is carried out 5 overnight and is monitored by HPLC and electrospray mass spectrometry. The ligation product is subsequently treated to remove protecting groups still present. The formyl group of Trp is cleaved by shifting the pH of the solution up to 9.0 with hydrazine and incubating for 1h at 37° C. Opening of the N-terminal thiazolidine ring further required the addition of solid methoxamine to a 0.5M final 10 concentration at pH3.5 and a further incubation for 2h at 37°C. A 10-fold excess of Tris(2-carboxyethyl)phosphine is added before preparative HPLC purification. Fractions containing the polypeptide chain are identified by ESMS, pooled and lyophilized.

The ligation of fragments 4 and 5 is performed at pH7.0 in 6 M GuHCl. The concentration of each reactant is 8mM, and 1% benzylmercaptan and 1% thiophenol were added to create a 15 reducing environment and to facilitate the ligation reaction. An almost quantitative ligation reaction is observed after overnight stirring at 37°C. At this point in the reaction, O-NH₂.HCl is added as a powder to a 0.1 M final concentration and hydrazine is added to shift the pH to 9.0, for the removal of the formyl group of any Trp residues. After a 1h incubation at 37°C, O-NH₂.HCl is further added to the solution to get a 0.5M final concentration, and the pH adjusted to 3.5 in order to open the N- 20 terminal thiazolidine ring. After 2h incubation at 37°C, ESMS is used to confirm the completion of the reaction. The reaction mixture is subsequently treated with a 10-fold excess of Tris(2-carboxyethylphosphine) over the peptide fragment and after 15min, the ligation product is purified using the preparative HPLC (e.g., C4, 20-60% CH₃CN, 0.5% per min), lyophilised, and stored at –20°C.

25 The same procedure is repeated for the remaining ligations with slight modification. Whenever the ligation takes place at an Ile-Cys or Val-Cys site, the ligation reaction is extended to 48h.

Polypeptide Folding

30 The full length peptide is refolded by air oxidation by dissolving the reduced lyophilized protein (about 0.1 mg/mL) in 1M GuHCl, 100mM Tris, 10mM methionine, pH 8.6 After gentle stirring overnight, the protein solution is purified by RP-HPLC as described above.

Example 4: Preparation of Pep714-related antibody compositions

Substantially pure Pep714-related peptide or a portion thereof is obtained. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per ml. Monoclonal or polyclonal antibodies to the protein are then prepared as described in the sections titled "Monoclonal antibodies" and "Polyclonal antibodies."

5 Briefly, to produce an anti-Pep714 related peptide monoclonal antibody, a mouse is repetitively inoculated with a few micrograms of the Pep714-related peptide or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the 10 spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing 15 clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, E., *Meth. Enzymol.* 70: 419 (1980), the disclosure of which is incorporated herein by reference in its entirety. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for 20 monoclonal antibody production are described in Davis, L. et al. *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2, the disclosure of which is incorporated herein by reference in its entirety.

For polyclonal antibody production by immunization, polyclonal antiserum containing 25 antibodies to heterogeneous epitopes in the Pep714-related peptide or a portion thereof are prepared by immunizing a mouse with the Pep714-related peptide or a portion thereof, which can be unmodified or modified to enhance immunogenicity. Any suitable nonhuman animal, preferably a non-human mammal, may be selected including rat, rabbit, goat, or horse.

Antibody preparations prepared according to either the monoclonal or the polyclonal 30 protocol are useful in quantitative immunoassays which determine concentrations of Pep714-related peptide in biological samples; or they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.